[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 284
1. Wang J, Shi YK, Wu LY, Wang JW, Yang S, Yang JL, Zhang HZ, Liu SM: Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):825-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for ovarian metastases from primary gastric cancer.
  • The purpose of this study was to analyze prognostic factors for ovarian metastases from primary gastric cancer, helping establish optimal strategy in ameliorating survival for this entity.
  • Clinical data of 68 consecutive patients histologically diagnosed with ovarian metastases from primary gastric cancer were accrued from 1096 cases with female gastric cancer.
  • Peritoneal metastases, lymphovascular involvement, and unilateral ovarian metastasectomy were independent unfavorable prognostic factors.
  • Innovative systemic treatments need to be explored in treatment of peritoneal metastases and lymphovascular involvement.
  • Bilateral oophorectomy was considered when ovarian metastases were histologically diagnosed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Ovarian Neoplasms / secondary. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892453.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 935E97BOY8 / Folic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Voermans RP, van Berge Henegouwen MI, de Cuba E, van den Broek FJ, van Acker G, Timmer R, Fockens P: Randomized, blinded comparison of transgastric, transcolonic, and laparoscopic peritoneoscopy for the detection of peritoneal metastases in a human cadaver model. Gastrointest Endosc; 2010 Nov;72(5):1027-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, blinded comparison of transgastric, transcolonic, and laparoscopic peritoneoscopy for the detection of peritoneal metastases in a human cadaver model.
  • OBJECTIVE: To compare transgastric peritoneoscopy (TGP) and transcolonic peritoneoscopy (TCP) to LAP, pairwise, in a randomized, blinded (to location and number of beads) human cadaver model with simulated peritoneal metastases.
  • DESIGN: Metastases were simulated by 2.5-mm, color-coded beads, which were placed into the peritoneal cavity via an open approach.
  • In previous porcine experiments, LAP resulted in a yield of 95%.
  • CONCLUSION: In this prospective, blinded, comparative trial in a human cadaver model, TCP was comparable to LAP in detecting simulated metastases.
  • [MeSH-major] Laparoscopy / methods. Natural Orifice Endoscopic Surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] Gastrointest Endosc. 2010 Nov;72(5):1034-5 [21034903.001]
  • (PMID = 20850736.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Alkhamesi NA, Roberts G, Ziprin P, Peck DH: Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction. Biomark Insights; 2007 Oct 08;2:377-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction.
  • INTRODUCTION: The development of peritoneal metastases is a significant clinical issue in the treatment of abdominal cancers and is associated with poor prognosis.
  • High metalloproteinases level significantly enhanced metastasis phenotype on tumors, a detrimental effect on surgical outcome.
  • Colorectal cancer cells were then introduced and allowed a direct and an indirect contact with the mesothelial layer.
  • CONCLUSIONS: ICAM-1-CD43 interaction plays a vital role in tumor cells-peritoneum adhesion and invasion, which is manifested by the increased production of MMPs leading to tumor invasion and peritoneal loco-regional.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] Cell Adhes Commun. 1997 Mar;4(6):439-55 [9177905.001]
  • [Cites] World J Surg. 1996 Jun;20(5):585-91; discussion 592 [8661635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54 [8610113.001]
  • [Cites] J Cell Physiol. 1993 Aug;156(2):235-46 [8344982.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 5;83(11):775-9 [1645772.001]
  • [Cites] Dis Colon Rectum. 1991 Aug;34(8):723-7 [1855433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):731-41 [3980270.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Biol Chem. 2004 Aug;385(8):755-61 [15449712.001]
  • [Cites] Cancer Control. 2003 May-Jun;10(3):224-38 [12794621.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Surgery. 2007 Jun;141(6):705-7 [17560245.001]
  • [Cites] J Control Release. 2007 May 14;119(1):121-7 [17382424.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):93-6 [17262739.001]
  • [Cites] Br J Oral Maxillofac Surg. 2006 Dec;44(6):482-6 [16338034.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):449-59 [16320108.001]
  • [Cites] Surg Endosc. 2005 Aug;19(8):1142-6 [16021376.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1802-10 [16051479.001]
  • [Cites] J Immunol. 1998 Mar 15;160(6):2967-73 [9510201.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):511-4 [11956618.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H983-9 [11834496.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):57-62 [11795999.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):71-8 [9096668.001]
  • (PMID = 19662219.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717821
  • [Keywords] NOTNLM ; CD43 / Colorectal cancer / Heparin / ICAM-1 / MMP-2 and MMP-9 / Mesothelial cells
  •  go-up   go-down


Advertisement
4. Huh JW, Park YA, Jung EJ, Lee KY, Kwon JE, Sohn SK: Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci; 2008 Oct;23(5):916-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
  • The adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors.
  • We report a case of 47-yr-old male, presented with sigmoid colon cancer with multiple liver and peritoneal metastases, in which there was a complete response for the primary colon cancer after administration of preoperative chemotherapy selected by ATP-CRA.
  • After twelve cycles of oxaliplatincapecitabine chemotherapy, abdominopelvic computed tomography revealed marked shrinkage of the liver metastases and positron emission tomography showed no uptake of 18F-fluoro-deoxy-glucose (FDG) either in the liver or peritoneum except localized uptake in the sigmoid colon.
  • The patient underwent an anterior resection and radiofrequency ablation of the liver metastases, which resulted in a macroscopic curative resection of the cancer cells.
  • Histological examination revealed no residual cancer cells in the resected specimen of the sigmoid colon.
  • This result suggested that preoperative chemotherapy chosen by ATP-CRA may be useful for treating advanced colon cancer with unresectable liver and peritoneal metastases.
  • [MeSH-major] Adenosine Triphosphate / metabolism. Antineoplastic Agents / pharmacology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Medical Oncology / methods. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Positron-Emission Tomography. Remission Induction. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):18-24 [10813118.001]
  • [Cites] J Gastroenterol. 2000;35(11):864-9 [11085497.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):599-602 [15185104.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1625-31 [10334552.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • (PMID = 18955806.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8L70Q75FXE / Adenosine Triphosphate; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2579999
  •  go-up   go-down


5. Köninger J, Wente MN, Müller-Stich BP, di Mola FF, Gutt CN, Hinz U, Müller MW, Friess H, Büchler MW: R2 resection in pancreatic cancer--does it make sense? Langenbecks Arch Surg; 2008 Nov;393(6):929-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R2 resection in pancreatic cancer--does it make sense?
  • BACKGROUND: The goal of surgical treatment in patients with pancreatic cancer is the complete resection of tumor tissue; however, the intraoperative appraisal of resectability can be difficult.
  • PATIENTS: We analyzed 38 patients with pancreatic cancer with remaining macroscopic tumor tissue after pancreatic resection, as R0 resection was not possible.
  • Patients were compared to 46 patients with unresectable cancer without distant metastases or peritoneal carcinomatosis, in which a bypass procedure was performed.
  • CONCLUSION: Tumor debulking is not a treatment option in patients with advanced pancreatic cancer, but the patient is not at a disadvantage compared to bypass procedures if tumor tissue remains and R0 resection cannot be achieved after surgical exploration.
  • [MeSH-major] Neoplasm, Residual / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Blood Loss, Surgical / mortality. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Palliative Care. Pancreas / pathology. Pancreaticoduodenectomy / methods. Postoperative Complications / etiology. Postoperative Complications / mortality. Prognosis. Prospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 24;322(3):943-9 [15336555.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):541-53 [2461172.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):721-9 [8799420.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):471-7 [15672431.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):312-23 [11561607.001]
  • [Cites] Surgery. 2007 Jan;141(1):1-6 [17188161.001]
  • [Cites] World J Surg. 1999 Sep;23(9):954-9 [10449827.001]
  • [Cites] Surgery. 2006 Feb;139(2):188-96 [16455327.001]
  • [Cites] J Surg Oncol. 1996 Jan;61(1):7-11; discussion 11-3 [8544466.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):598-604 [17667928.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):221-8 [18154768.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):429-42 [9783792.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):681-6 [16739338.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):410-4; discussion 414-5 [7638998.001]
  • [Cites] Ann Surg. 1996 Jun;223(6):718-25; discussion 725-8 [8645045.001]
  • (PMID = 18309512.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Weickert U, Jakobs R, Riemann JF: Diagnostic laparoscopy. Endoscopy; 2005 Jan;37(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its greater expense, fluorescence laparoscopy may have advantages over white-light laparoscopy in the diagnosis of small tumor seeding.
  • The unchanged superiority of laparoscopy over other imaging modalities for detecting small superficial liver metastases and peritoneal seeding has been clearly demonstrated.
  • Whether cytological investigation of peritoneal washing can add relevant information to laparoscopy remains a matter of debate.
  • A transgastric approach to the peritoneal cavity for diagnostic and therapeutic purposes, the feasibility of which has been demonstrated in a porcine model, is an exciting innovation with as yet unforeseeable implications.
  • [MeSH-major] Laparoscopy. Liver Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Humans. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657855.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


7. Misdraji J: Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med; 2010 Jun;134(6):864-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low grade appendiceal mucinous neoplasms can spread to the peritoneum as pseudomyxoma peritonei even though they are not obviously invasive in the appendix.
  • During the past several decades, several problematic issues surrounding this enigmatic tumor have been debated in the literature, including appropriate nomenclature for the appendiceal tumors and their peritoneal metastases.
  • Next reviewed is the largely resolved controversy about whether ovarian mucinous tumors in this setting are separate primaries or are metastases from the appendiceal tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524864.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


8. Odashiro AN, Pereira PR, Odashiro Miiji LN, Nguyen GK: Angiosarcoma of the gallbladder: case report and review of the literature. Can J Gastroenterol; 2005 Apr;19(4):257-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were multiple hepatic, splenic, ovarian and peritoneal metastases and a massive hemoperitoneum consisting of 8 L of blood and blood clots.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Hemangiosarcoma / diagnosis
  • [MeSH-minor] Cholecystectomy. Cholecystitis / diagnosis. Cholelithiasis / diagnosis. Fatal Outcome. Female. Hemoperitoneum / etiology. Humans. Middle Aged. Postoperative Complications

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861270.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 11
  •  go-up   go-down


9. Orsenigo E, Di Palo S, Vignali A, Staudacher C: Laparoscopic excision of duodenal schwannoma. Surg Endosc; 2007 Aug;21(8):1454-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Benign duodenal tumours are rare and less common than malignant tumours.
  • Schwannoma is an ectodermal neoplasm arising from the nerve sheath that envelops axons.
  • No macroscopic peritoneal seedling was found.
  • The resected lesion was then placed in a retrieval bag and extracted through the port incision.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2003 Jul;33(7):364-6 [12949065.001]
  • [Cites] Minerva Chir. 1998 May;53(5):419-26 [9780634.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):62-7 [8554153.001]
  • [Cites] Chirurg. 1997 Feb;68(2):159-67 [9156983.001]
  • [Cites] Chir Ital. 1979 Dec;31(6):1150-61 [554761.001]
  • [Cites] Arq Gastroenterol. 1996 Oct-Dec;33(4):221-4 [9302337.001]
  • [Cites] Chir Ital. 2004 May-Jun;56(3):443-8 [15287645.001]
  • (PMID = 17177083.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Kodera Y, Nakanishi H, Ito S, Misawa K, Ito Y, Nakayama G, Koike M, Fujiwara M, Yamamura Y, Nakao A: Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Res; 2009 Oct;29(10):4033-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer.
  • BACKGROUND: L1, a 200-220 kDa transmembrane glycoprotein of the immunoglobulin superfamily, has been shown to affect prognosis of various types of cancer and was shown to enhance peritoneal metastasis in ovarian cancer in vivo.
  • PATIENTS AND METHODS: Immunostaining with anti-L1 antibody was performed with 72 surgically resected pT3-stage gastric cancer specimens.
  • RESULTS: L1 was detected in 15 specimens (21%), more often among the intestinal-type cancer.
  • No correlation was observed between L1 expression and presence of free cancer cells in the peritoneal cavity or development of peritoneal carcinomatosis during the follow-up.
  • Nevertheless, prognosis of patients with L1-positive cancer was significantly inferior (p=0.024), particularly among the diffuse-type cancer cases.
  • However, its association with the formation of peritoneal metastases or the presence of free cancer cells in the abdominal cavity was not observed.
  • Further study to identify the role of L1 in gastric cancer progression and metastasis is warranted.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846947.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


11. Barbolina MV, Adley BP, Shea LD, Stack MS: Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer; 2008 Apr 1;112(7):1632-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion.
  • BACKGROUND: Although metastatic disease is the primary cause of death from epithelial ovarian carcinoma, to the authors' knowledge the cellular mechanisms that regulate intraperitoneal metastasis are largely unknown.
  • METHODS: Immunohistochemistry using primary and metastatic ovarian carcinoma samples was employed to detect expression of Wilms tumor gene protein 1 (WT1).
  • RESULTS: To model intraperitoneal invasion in vitro, ovarian cancer cells were cultured in a 3D collagen microenvironment.
  • WT1 expression was prevalent in primary ovarian tumors and was retained in paired peritoneal metastases.
  • Functional studies supported a role for WT1 in intraperitoneal invasion, because siRNA knockdown of WT1 expression reduced the ability of ovarian cancer cells to invade 3D collagen gels.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260155.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA086984; United States / NCI NIH HHS / CA / R01 CA109545; United States / NCI NIH HHS / CA / R01 CA86984
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type III; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / WTAP protein, human
  •  go-up   go-down


12. Badmus TA, Adesunkanmi AR, Agbakwuru CA, Salako AA, Uhunmwagho O, Eziyi AK: Giant renal oncocytoma masquerading as infiltrating renal cell carcinoma: case report and literature review. Cent Afr J Med; 2006 Jan-Feb;52(1-2):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of giant renal oncocytoma in a patient with synchronous bladder tumour, with pre-operative clinical, urographic and ultrasound features of locally advanced renal cell carcinoma (RCC).
  • There was no tumour extension to the renal vein, no peritoneal seedling, no nodal metastasis and no ascites.
  • This presentation, besides highlighting the possible giant nature of RO, also illustrates the malignant potential of RO to infiltrate contiguous structures and mimics infiltrating RCC.
  • In view of the difficulties at establishing pre-operative diagnosis in this disease and because nephron-sparing surgery is curative, especially for the well-circumscribed tumours, RO should be considered in the management of patients with features of infiltrating RCC.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged


13. Kajikawa M, Kondo K, Kataoka M, Hatsuno T, Kinoshita M, Horisawa M, Moritani S, Ichihara S: [A case of endocrine cell carcinoma (small cell carcinoma) of duodenum]. Nihon Shokakibyo Gakkai Zasshi; 2006 May;103(5):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fiberscopic examination revealed a circumferential tumor in the extra-ampullary duodenal second portion.
  • Pylorus-preserving pancreaticoduodenectomy with partial transversocolectomy was performed, and intraoperative washing cytology detected tumor cells in the peritoneal cavity.
  • Although she discharged from hospital uneventfully, she died 11 months later of multiple liver metastases and peritoneal dissemination.
  • This case showed the high malignant potential of this tumor.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Duodenal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734258.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Kyriazi S, Kaye SB, deSouza NM: Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol; 2010 Jul;7(7):381-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.
  • Peritoneal metastases are often the first presentation of ovarian malignancy.
  • Standard CT, however, frequently fails to identify small sites of peritoneal spread.
  • We describe the emerging role of functional imaging techniques, such as radioimmunoscintigraphy, PET/CT, diffusion-weighted MRI, dynamic contrast-enhanced MRI, and magnetic resonance spectroscopy in staging ovarian cancer and assessing treatment response.
  • The combination of functional information with conventional anatomical visualization holds promise to accurately characterize peritoneal disease, and provides noninvasive biomarkers of therapeutic performance and patient prognosis.
  • [MeSH-major] Diagnostic Imaging / methods. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20386556.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 143
  •  go-up   go-down


15. Li SD, Howell SB: CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm; 2010 Feb 1;7(1):280-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
  • Intraperitoneal (ip) chemotherapy increases the survival of optimally debulked patients with ovarian cancer due to direct access of the drug to tumor nodules growing on the peritoneal surface.
  • To further improve efficacy, we sought to develop a cisplatin-loaded microparticle that would target to CD44 on cancer cells when injected ip.
  • Clearance of Hyplat from the mouse peritoneum was reduced by 7-fold and tumor uptake was increased by 2- to 3-fold in CD44-positive but not CD44-negative tumor models compared to that attained with free cisplatin.
  • Hyplat was more effective than cisplatin at slowing the growth of intraperitoneally inoculated A2780 ovarian cancer cells and improving survival thus demonstrating the potential of Hyplat to enhance the efficacy of ip chemotherapy.
  • [MeSH-major] Antigens, CD44 / metabolism. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994852.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents; 0 / CD44 protein, human; 9004-61-9 / Hyaluronic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, Allameh AA: High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr Purif; 2005 Nov;44(1):32-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The high binding activity to MUC1 antigen purified from ascitic fluid (of patients with small-cell lung aggressive carcinoma and metastasis to peritoneum) and the very close similarity of these molecules to human VHs illustrated the potential application of these novel products as an immunodiagnostic and immunotherapeutic reagent.
  • [MeSH-minor] Animals. Camels / immunology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / immunology. Carcinoma, Small Cell / secondary. Humans. Immunologic Tests / methods. Mice. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / secondary. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Recombinant Proteins / isolation & purification

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922625.001).
  • [ISSN] 1046-5928
  • [Journal-full-title] Protein expression and purification
  • [ISO-abbreviation] Protein Expr. Purif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Variable Region; 0 / Mucin-1; 0 / Recombinant Proteins
  •  go-up   go-down


17. Zhi K, Shen X, Zhang H, Bi J: Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers. J Exp Clin Cancer Res; 2010;29:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.
  • BACKGROUND: The prognosis of gastric cancer patients is difficult to predict because of defects in establishing the surgical-pathological features.
  • Cancer-associated fibroblasts (CAFs) have been found to play prominent role in promoting tumor growth, invasion and metastasis.
  • Thus raises the hypothesis that the extent of CAFs prevalence may help to establish the prognosis of gastric cancer patients.
  • The extent of CAFs' prevalence was graded according to immunochemical staining, and correlation was further analyzed between CAFs' prevalence and other tumor characteristics which may influence the prognosis of gastric cancer patients.
  • RESULTS: Nearly 80 percent of normal gastric tissues were negative or weak positive for CAFs staining, while more than 60 percent of gastric cancer tissues were moderate or strong positive for CAFs staining.
  • Realtime-PCR results also showed significant elevated expression of FAP, SDF-1 and TGF-beta1 in gastric cancer tissues compared to normal gastric tissues.
  • Further analysis showed that CAFs' prevalence was correlated with tumor size, depth of the tumor, lymph node metastasis, liver metastasis or peritoneum metastasis.
  • CONCLUSIONS: Reactive cancer associated fibroblasts (CAFs) were frequently accumulated in gastric cancer tissues, and the prevalence of CAFs was correlated with tumor size, depth of the tumor and tumor metastasis, thus give some supports for establishing the prognosis of the gastric cancer patients.
  • [MeSH-major] Fibroblasts / pathology. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Calcium-Binding Proteins / genetics. Calcium-Binding Proteins / metabolism. Case-Control Studies. Collagen Type I / genetics. Collagen Type I / metabolism. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6021-5 [12414622.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Am J Pathol. 1981 Sep;104(3):206-16 [6170230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 [2402505.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):909-15 [8217606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):393-405 [7615639.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Mol Diagn Ther. 2006;10(6):345-52 [17154651.001]
  • [Cites] Arch Biochem Biophys. 2007 Jan 15;457(2):177-86 [17174263.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1736-41 [17363526.001]
  • [Cites] Am Surg. 2007 Apr;73(4):359-66 [17439029.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4869-77 [17495323.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Sep;22(9):1435-42 [17573829.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Biochemistry. 2008 Jan 22;47(3):1076-86 [18095711.001]
  • [Cites] Nat Genet. 2008 May;40(5):650-5 [18408720.001]
  • [Cites] Ultrastruct Pathol. 2008 May-Jun;32(3):89-96 [18570153.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19864-71 [18495668.001]
  • [Cites] Pancreas. 2008 Aug;37(2):154-8 [18665076.001]
  • [Cites] Trends Genet. 2009 Jan;25(1):30-8 [19054589.001]
  • [Cites] J Pathol. 2009 Jun;218(2):192-200 [19224540.001]
  • [Cites] Endocr Relat Cancer. 2009 Sep;16(3):663-73 [19556286.001]
  • [Cites] Digestion. 2009;80(3):148-58 [19713703.001]
  • [Cites] J Korean Med Sci. 2009 Dec;24(6):1158-64 [19949675.001]
  • [Cites] J Clin Invest. 2009 Dec;119(12):3613-25 [19920354.001]
  • [Cites] Med Clin (Barc). 2010 Feb 6;134(3):123-6 [19944435.001]
  • [Cites] Semin Cell Dev Biol. 2010 Feb;21(1):19-25 [19857592.001]
  • [Cites] Mol Ther. 2001 Feb;3(2):149-59 [11237671.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • (PMID = 20529313.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Calcium-Binding Proteins; 0 / Collagen Type I; 0 / FSP1 protein, human; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC2892440
  •  go-up   go-down


18. Ogawa M, Kosaka N, Choyke PL, Kobayashi H: H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol; 2009 Jul 17;4(7):535-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo molecular imaging with target-specific activatable "smart" probes, which yield fluorescence only at the intended target, enables sensitive and specific cancer detection.
  • To demonstrate the fluorescence activation effect during in vivo fluorescence endoscopic molecular imaging, a highly quenched probe, avidin-TAMRA, or a minimally quenched probe, avidin-Alexa488, was administered into mice with ovarian metastases to the peritoneum.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2006 Oct;12(10):1213-9 [17013385.001]
  • [Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72 [15601762.001]
  • [Cites] J Chem Inf Comput Sci. 1987 Feb;27(1):21-35 [3558506.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3271-5 [15132531.001]
  • [Cites] J Am Chem Soc. 2002 Jan 16;124(2):196-204 [11782171.001]
  • [Cites] Science. 2001 May 18;292(5520):1385-8 [11359013.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2791-9 [17363601.001]
  • [Cites] J Am Chem Soc. 2007 Apr 4;129(13):3918-29 [17352471.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6335-43 [17975145.001]
  • [Cites] Anal Sci. 2008 Jan;24(1):51-3 [18187849.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Bioconjug Chem. 2008 Aug;19(8):1735-42 [18610943.001]
  • [Cites] Nat Med. 2009 Jan;15(1):104-9 [19029979.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):232-9 [19139133.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1268-72 [19176373.001]
  • [Cites] Mol Pharm. 2009 Mar-Apr;6(2):386-95 [19718793.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):27-35 [10585741.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • (PMID = 19480464.001).
  • [ISSN] 1554-8937
  • [Journal-full-title] ACS chemical biology
  • [ISO-abbreviation] ACS Chem. Biol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Receptors, Cell Surface; 0 / Rhodamines; 0 / galactose receptor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS122733; NLM/ PMC2743556
  •  go-up   go-down


19. Tougeron D, Hamidou H, Dujardin F, Maillard C, Di Fiore F, Michel P: Unusual skeletal muscle metastasis from gastric adenocarcinoma. Gastroenterol Clin Biol; 2009 Jun-Jul;33(6-7):485-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual skeletal muscle metastasis from gastric adenocarcinoma.
  • Patients with gastric adenocarcinoma frequently develop hepatic metastases or peritoneal carcinosis but involvement of the skeletal muscle is extremely rare.
  • We report the case of a 71-year-old man with a painful soft tissue mass in the right shoulder.
  • Surgical exploration with biopsy showed skeletal muscle metastasis from the gastric adenocarcinoma in the deltoid muscle.
  • Chemoradiotherapy resulted in complete regression of symptoms from the metastatic lesion.
  • Based on this case study, the difficulty of diagnosing skeletal muscle metastases, the prognosis and treatment options are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Muscle Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477611.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Longacre TA, Oliva E, Soslow RA, Association of Directors of Anatomic and Surgical Pathology: Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol; 2007 Aug;38(8):1160-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By convention, epithelial tumors that involve the ovary or peritoneal surfaces are considered to have arisen either in the ovary or endometrium or, in absence of significant ovarian or endometrial involvement, in the peritoneum, irrespective of whether or not the fallopian tube mucosa is also involved.
  • An alternative hypothesis for the origin of ovarian and peritoneal carcinoma has even been proposed, based on the concept of transport and implantation of malignant cells from the tube to the ovary and peritoneum.
  • Malignancies in the fallopian tube can therefore be classified as (1) arising primarily in the fallopian tube, either from preexisting endometriosis (or more rarely, a mature teratoma) or directly from tubal mucosa with metastasis to adjacent tissues;.
  • (2) arising in the ovary, endometrium, or peritoneum with metastasis to the tubal serosa or mucosa; or (3) arising primarily in the fallopian tube as well as in the ovary, endometrium, or peritoneum (simultaneous primary tumors).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Apr;40(4):603-4 [19289185.001]
  • (PMID = 17270244.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Abbas SM, Merrie AE: Resection of peritoneal metastases causing malignant small bowel obstruction. World J Surg Oncol; 2007;5:122
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of peritoneal metastases causing malignant small bowel obstruction.
  • BACKGROUND: Resection of peritoneal metastases has been shown to improve survival in patients with abdominal metastatic disease from abdominal or extra abdominal malignancy.
  • This study evaluates the benefit of peritoneal metastatic resection in patients with malignant small bowel obstruction and a past history of treated cancer.
  • PATIENTS AND METHODS: Patients undergoing laparotomy for resection of peritoneal metastases from recurrence of previous cancer between 1992-2003 were reviewed retrospectively.
  • Data were collected about type of primary cancer, interval to recurrence, extent of the disease and completeness of resection, morbidity and mortality and long-term survival.
  • RESULTS: Between 1992 and 2003 there were 79 patients (median age 62, range 19-91) who had laparotomy for small bowel obstruction due to recurrent cancer.
  • The primary cancer was colorectal (31), gynaecologic cancer (19), melanoma (16) and others (13).
  • Median survival was 5 months; patients with history of colorectal cancer had better survival than other cancer (median survival 7 months vs. 4 months; p = 0.02).
  • CONCLUSION: Laparotomy for small bowel obstruction is a worthwhile option for patients with malignant small bowel obstruction.
  • [MeSH-major] Intestinal Obstruction / surgery. Intestine, Small. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Surg. 2000 Oct;43(5):353-8 [11045093.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):862-9 [11313174.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):632-7 [11569777.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):283-90 [11804881.001]
  • [Cites] Nucl Med Commun. 2002 Oct;23(10):975-82 [12352596.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):519-28 [13678719.001]
  • [Cites] Invest Radiol. 2004 Jan;39(1):8-12 [14701983.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1420-9 [15007086.001]
  • [Cites] Br J Surg. 1984 Dec;71(12):933-5 [6208964.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):209-13 [1691417.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):367-71 [2022140.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):624-8 [1727026.001]
  • [Cites] Arch Surg. 1995 Aug;130(8):832-6; discussion 836-7 [7632142.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • (PMID = 17958911.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2206041
  •  go-up   go-down


22. Zhu ZG, Tang R, Yan M, Chen J, Yang QM, Li C, Yao XX, Zhang J, Yin HR, Lin YZ: Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study. Dig Surg; 2006;23(1-2):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study.
  • AIMS: This study was undertaken to investigate the clinical effects and safety of intraoperative peritoneal hyperthermic chemotherapy (IPHC) for advanced gastric cancer (AGC) patients.
  • Among these cases, 96 patients without macroscopic peritoneal metastases were selected for the prophylactic study, 22 with peritoneal metastases were selected for the therapeutic study.
  • RESULTS: For the prophylactic study, the IPHC procedure improves postoperative survival rate and decrease the incidence of peritoneal recurrence, and is an independent prognostic factor for these patients.
  • It is especially beneficial for patients without peritoneal metastasis due to the reduction of postoperative peritoneal recurrence.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763374.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, Hopt UT, Schaechtele C, von Dobschuetz E, Massing U: Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas; 2009 Apr;38(3):330-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.
  • OBJECTIVES: Test the efficacy of liposomal gemcitabine (GemLip) on primary tumor and metastases using the pancreatic tumor cell line AsPC1 implanted orthotopically into nude mice.
  • GemLip and empty liposomes both significantly interfered with the metastatic spread to the liver, as measured using luciferase assays (GemLip, *P = 0.01; empty liposomes, *P = 0.036).
  • In addition, they showed effects against spleen, as well as peritoneal metastases.
  • CONCLUSIONS: GemLip presents an effective new formulation of gemcitabine, combining the targeting and protective features of the liposomes with their antimetastatic effects to target pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Deoxycytidine / analogs & derivatives. Liposomes / pharmacology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Drug Resistance, Neoplasm. Female. Luciferases / genetics. Mice. Mice, Nude. Neoplasm Transplantation. Transduction, Genetic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142174.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.13.12.- / Luciferases
  •  go-up   go-down


24. Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, Hirakawa K: Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology; 2008;74(1-2):69-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer.
  • AIMS: The clinical significance of chemokine receptor CCR7 expression in pancreatic ductal cancer was investigated.
  • METHODS: Immunohistochemical staining of 89 pancreatic cancers treated macroscopically with curative resection without hematogenous metastases or peritoneal dissemination were analyzed in association with clinicopathological data.
  • RESULTS: The positivity of CCR7 in pancreatic cancer was 32.6% (29/89).
  • A significant correlation was detected between CCR7-positive expression and lymph node metastasis.
  • CONCLUSION: The survival impact of CCR7 expression on resectable pancreatic cancer may be associated with lymphatic spread.
  • The results from the present study should foster further investigation of treatments using an inhibitor for the CCR7 protein to improve the survival of pancreatic cancer.
  • [MeSH-major] Lymphatic Metastasis / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Receptors, CCR7 / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18544997.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Receptors, CCR7
  •  go-up   go-down


25. Ina K, Furuta R, Kataoka T, Nishio T, Nagao S, Kayukawa S, Masaki A, Ando T, Goto H: [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
  • Two unresectable advanced gastric cancer cases with peritoneal metastases were successfully treated by the combination therapy of S-1 and paclitaxel.
  • Case 1: 65-year-old male (performance status: PS 3) with type 1 gastric cancer with malignant ascites.
  • Case 2: 66-year-old male (PS3) with peritoneal metastases whose primary gastric lesion was surgically resected.
  • Combination therapy of S-1 and paclitaxel can be highly recommended for patients with inoperable gastric cancer with poor PS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542719.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Zhu ZG, Tang R, Yan M, Chen J, Yang QM, Li S, Yao XX, Zhang J, Yin HR, Lin YZ: [Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan;9(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer].
  • OBJECTIVE: To investigate the clinical effect of intraoperative peritoneal hyperthermic chemotherapy (IPHC) for advanced gastric cancer (AGC).
  • Among these cases, 96 patients without macroscopic peritoneal metastases were selected for prophylactic study, including 42 cases with IPHC and 54 cases without IPHC as control.
  • Other 22 patients with macroscopic peritoneal metastases were selected for therapeutic study, including 10 cases with IPHC and 12 without IPHC.
  • Postoperative survival rate and peritoneal recurrence were compared.
  • More patients in the control group suffered from peritoneal recurrence than those in IPHC group (34.7% vs 10.3%).
  • CONCLUSION: IPHC procedure can improve the prognosis of AGC patients with serosal invasion, reduce the risk for peritoneal recurrence, and is an independent prognostic factor.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437366.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


27. Jonas S, Mittler J, Pascher A, Theruvath T, Thelen A, Klupp J, Langrehr JM, Neuhaus P: Extended indications in living-donor liver transplantation: bile duct cancer. Transplantation; 2005 Sep 27;80(1 Suppl):S101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended indications in living-donor liver transplantation: bile duct cancer.
  • Four patients suffering from Klatskin tumors are alive without recurrence; both patients suffering from intrahepatic cholangiocarcinoma are alive with bone and peritoneal metastases.


28. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P: Pancreatic adenocarcinoma. Eur Radiol; 2007 Mar;17(3):638-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases.
  • By the time of diagnosis, at least 80% of tumors are unresectable.
  • Moreover, it is not very accurate for determining nonresectability because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed.
  • It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Endosonography. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):849-55 [10715057.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Abdom Imaging. 1997 Jul-Aug;22(4):429-33 [9157866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):204-7 [9013536.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):700-3 [16120921.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Pancreatology. 2001;1(6):610-24 [12120244.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):649-52 [9490946.001]
  • [Cites] Eur Radiol. 2005 Nov;15 Suppl 4:D96-9 [16479656.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):231-4 [11246351.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiology. 1997 Nov;205(2):513-8 [9356637.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Radiology. 1991 Aug;180(2):337-9 [1906189.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Br J Radiol. 2000 Nov;73(875):1165-9 [11144793.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Radiology. 1993 Mar;186(3):795-8 [8430190.001]
  • [Cites] Radiographics. 2005 Jul-Aug;25(4):949-65 [16009817.001]
  • [Cites] Radiology. 2001 Oct;221(1):107-16 [11568327.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Eur Radiol. 2005 Jun;15(6):1256-62 [15627187.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Invest Radiol. 1999 Sep;34(9):589-95 [10485075.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Br J Radiol. 1998 May;71(845):492-6 [9691893.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 5:M42-9 [14989611.001]
  • [Cites] Radiology. 2002 Dec;225(3):759-65 [12461258.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):119-23 [9207510.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] Eur Radiol. 1996;6(1):14-8 [8797944.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):677-84 [10701608.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12 ):2658-61 [16393216.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):2998-3008 [12439582.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Magn Reson Imaging. 2000 Aug;12 (2):261-8 [10931589.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] Rofo. 2004 Nov;176(11):1624-33 [15497081.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):743-9 [12439309.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 17021700.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 65
  •  go-up   go-down


29. Lee YT, Ng EK, Hung LC, Chung SC, Ching JY, Chan WY, Chu WC, Sung JJ: Accuracy of endoscopic ultrasonography in diagnosing ascites and predicting peritoneal metastases in gastric cancer patients. Gut; 2005 Nov;54(11):1541-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoscopic ultrasonography in diagnosing ascites and predicting peritoneal metastases in gastric cancer patients.
  • BACKGROUND: Preoperative diagnosis of peritoneal metastases (PM) is difficult in patients with gastric cancer (GC).
  • The diagnosis of PM was confirmed by histopathology or peritoneal fluid cytology.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / ultrasonography. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascites / ultrasonography. Endosonography. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1999;29(2):111-5 [10030734.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):520-4 [10027323.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2509-12 [10484016.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):336-9 [11522974.001]
  • [Cites] J Clin Gastroenterol. 2002 Oct;35(4):321-7 [12352295.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1407-12 [12960184.001]
  • [Cites] Gastrointest Endosc. 2004 Apr;59(4):471-4 [15044880.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1521-5 [15083179.001]
  • [Cites] Ann R Coll Surg Engl. 1974 May;54(5):219-28 [4275295.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1984;25(5):375-8 [6391091.001]
  • [Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]
  • [Cites] Br J Surg. 1989 Oct;76(10):1036-9 [2532050.001]
  • [Cites] Gut. 1991 May;32(5):479-82 [2040468.001]
  • [Cites] Gut. 1993 May;34(5):604-10 [8504959.001]
  • [Cites] Gastrointest Endosc. 1994 Jul-Aug;40(4):442-6 [7926534.001]
  • [Cites] J Trauma. 1995 Aug;39(2):375-80 [7674411.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jul;5(3):549-57 [7582581.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):872-5 [9149204.001]
  • [Cites] Surg Laparosc Endosc. 1998 Apr;8(2):132-5 [9566568.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):27-32 [9915239.001]
  • [CommentIn] Gut. 2006 Oct;55(10):1524; author reply 1524 [16966710.001]
  • (PMID = 15955787.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774738
  •  go-up   go-down


30. Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G, Gruppo Oncologico dell'Italia Meridionale: Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol; 2006 Jun;17 Suppl 7:vii73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
  • BACKGROUND: The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy.
  • Objective responses were recorded at loco-regional disease, liver and nodal metastases.
  • Lung and peritoneal metastases did not respond.
  • CONCLUSION: The GEM/CDDP regimen is active against advanced and/or metastatic BTC with a favourable toxicity profile.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760299.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Fadiora SO, Mabayoje VO, Oboro VO, Ojemakinde KA, Bello TO, Adeniji AA: Ovarian non-Hodgkin's lymphoma presenting as obstructive jaundice - a case report. Niger Postgrad Med J; 2008 Dec;15(4):267-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To highlight the importance of considering abdominal Lymphoma as a differential diagnosis in the management of obstructive jaundice.
  • Massive peritoneal seedling involved the whole abdomen and pelvis was noted.
  • INVESTIGATION/DIAGNOSIS: Histology of excision biopsy revealed high grade Non-Hodgkins's Lymphoma.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Sedimentation. Diagnosis, Differential. Female. Humans. Laparotomy. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169347.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


32. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, Chiba T, Hagiwara A: Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res; 2005 Sep 15;11(18):6479-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
  • PURPOSE: Our previous results suggested that a lack of RUNX3 function contributed to human gastric carcinogenesis, but the role of RUNX3 in progression and metastasis remains unclear.
  • We examined RUNX3 expression in clinical samples of peritoneal metastases in gastric cancers.
  • Changes in metastatic potential were assessed in animal experiments using stable RUNX3 transfectants of gastric cancer cells.
  • EXPERIMENTAL DESIGN AND RESULTS: Significant down-regulation of RUNX3 through methylation on the promoter region was observed in primary tumors (75%) as well as in all clinical peritoneal metastases of gastric cancers (100%) compared with normal gastric mucosa.
  • Interestingly, it strongly inhibited peritoneal metastases of gastric cancers in animal model (P < 0.01).
  • Microarray analysis identified approximately 28 candidate genes under the possible downstream control of RUNX3, some of these genes were considered to be possibly involved in peritoneal metastases, which were related to signal transduction (vav3, TOLL-like receptor, MAPKK, MET, S1 00A1 1, and cathepsin E), apoptosis (caspase 9), immune responses (CD55 and TLR1O), and cell adhesion (sialyltransferase 1 and galectin 4).
  • CONCLUSION: These results indicate that silencing of RUNX3 affects expression of important genes involved in aspects of metastasis including cell adhesion, proliferation, apoptosis, and promoting the peritoneal metastasis of gastric cancer.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Silencing / physiology. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology. Transcription Factors / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Base Sequence. Blotting, Northern. Cell Line, Tumor. Cell Proliferation / drug effects. Core Binding Factor Alpha 3 Subunit. DNA Methylation. Down-Regulation / genetics. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Mice. Mice, Nude. Molecular Sequence Data. Neoplasm Transplantation. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Nucleic Acid. Transfection. Transforming Growth Factor beta / pharmacology. Transforming Growth Factor beta1. Transplantation, Heterologous. Up-Regulation / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166423.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Runx3 protein, human; 0 / Runx3 protein, mouse; 0 / TGFB1 protein, human; 0 / Tgfb1 protein, mouse; 0 / Transcription Factors; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


33. Grünberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Bläuenstein P, Ametamey S, Maecke HR, Schubiger PA: In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res; 2005 Jul 15;11(14):5112-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The L1 cell adhesion protein is overexpressed in tumors, such as neuroblastomas, renal cell carcinomas, ovarian carcinomas, and endometrial carcinomas, and represents a target for tumor diagnosis and therapy with anti-L1-CAM antibody chCE7.
  • Positron emission tomography imaging allowed clear visualization of s.c. xenografts and peritoneal metastases and a detailed assessment of whole-body tracer distribution.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Immunoconjugates; 0 / Immunoglobulin Fragments; 0 / Neural Cell Adhesion Molecule L1; 0 / Radioisotopes; 5H0DOZ21UJ / Lutetium
  •  go-up   go-down


34. Versaci A, Macrì A, Ieni A, Terranova M, Leonello G, Saladino E, Speciale G, Famulari C: [Gastrointestinal stromal tumour: our experience]. Chir Ital; 2009 Mar-Apr;61(2):161-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging difficulties impede an early diagnosis; sometimes these tumours represent an unexpected intraoperative finding or an emergency abdominal picture.
  • The use of imatinib mesylate is recommended today in the treatment of advanced GIST, especially in cases with liver and peritoneal metastases.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536989.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


35. Tsili AC, Tsampoulas C, Charisiadi A, Kalef-Ezra J, Dousias V, Paraskevaidis E, Efremidis SC: Adnexal masses: accuracy of detection and differentiation with multidetector computed tomography. Gynecol Oncol; 2008 Jul;110(1):22-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiplanar reformatted images were evaluated for the presence of an adnexal mass and differentiation between benign and malignant ones, using the surgical and pathologic results as standard of reference.
  • CT findings used to diagnose malignancy were: diameter greater than 4 cm, presence of masses bilaterally, cystic-solid mass, necrosis in a solid lesion, cystic lesion with thick, irregular walls or septa and/or with papillary projections.
  • Presence of ascites, peritoneal metastases and lymphadenopathy was used to confirm malignancy.
  • RESULTS: Histopathologic examination demonstrated 143 adnexal mass lesions, 96 (67%) of which were benign and 47 (33%) malignant.
  • Multidetector CT detected 129 (90%) of the 143 adnexal masses, with an overall accuracy for the diagnosis of malignancy of 89.15%.
  • The MDCT findings that found more predictive of malignancy were the presence of papillary projections in a cystic lesion, necrosis in solid mass and peritoneal metastases.
  • [MeSH-major] Adnexal Diseases / pathology. Adnexal Diseases / radiography. Diagnosis, Differential

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486202.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Takahashi S, Hatake K, Katori M, Yamamoto N, Muto T: Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case. Surg Today; 2010 Mar;40(3):272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.
  • A 70-year-old woman with a pelvic tumor had undergone exploratory laparoscopy at another institution, which revealed many peritoneal nodules.
  • Immunohistochemical staining of a biopsy specimen of the peritoneal nodules was positive for KIT.
  • Laparotomy revealed complete regression of the peritoneal lesions.
  • We report this case to show that there is the possibility of curative salvage surgery after long-term imatinib treatment in some patients with peritoneal metastases of a GIST.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors / surgery. Ileal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] Ann Oncol. 2006 Sep;17 Suppl 10:x280-6 [17018739.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):270-9 [15685537.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):341-6 [17435538.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Gut. 2006 Apr;55(4):585-6 [16531543.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):176-84 [16858179.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1247-8 [17265116.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):347-52 [17435539.001]
  • (PMID = 20180084.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


37. Hosokawa A, Sugiyama T, Ohtsu A, Doi T, Hattori S, Kojima T, Yano T, Minashi K, Muto M, Yoshida S: Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol; 2007 Jul;42(7):533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
  • BACKGROUND: S-1, an oral fluoropyrimidine, has been shown to have excellent activity against gastric cancer in two phase II studies and is widely used in Japan.
  • However, the long-term outcomes of patients after S-1 monotherapy for metastatic gastric cancer are unclear.
  • The aim of this study was to investigate the long-term outcomes in metastatic gastric cancer patients who had initially received S-1 monotherapy.
  • METHODS: Ninety-two previously untreated patients with advanced gastric cancer received S-1 monotherapy as first-line chemotherapy at the National Cancer Center Hospital East, Kashiwa, Japan, and then the long-term outcomes and characteristics of long-term survivors were analyzed retrospectively.
  • Multivariate analysis showed that good performance status (P = 0.0004) and only one metastatic site (P = 0.0048) were significant independent prognostic factors.
  • Among 48 patients with a single metastatic site, 22 with peritoneal metastasis had longer survival times (median survival, 24 months) than patients with metastasis at other sites.
  • Among the nine 3-year survivors, six had peritoneal metastases alone.
  • CONCLUSIONS: The survival outcomes after S-1 monotherapy are promising, especially in patients with good performance status and a single metastatic site.
  • Our findings suggest that, among patients with a single metastatic site, those with peritoneal metastases alone have a chance for long-term survival.
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Drug Combinations. Female. Humans. Japan. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Gastric Cancer. 2002;5(1):47-50 [12021860.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Jpn J Clin Oncol. 2004 Nov;34(11):654-9 [15613554.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:13-8 [12775014.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):889-92 [12828112.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):811-5 [12066214.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Cancer Invest. 2003;21(1):14-20 [12643005.001]
  • [Cites] Gastric Cancer. 2005;8(1):6-11 [15747168.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • (PMID = 17653648.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


38. Teo M, Foo KF, Koo WH, Wong LT, Soo KC: Lessons learned from initial experience with peritonectomy and intra-peritoneal chemotherapy infusion. World J Surg; 2006 Dec;30(12):2132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons learned from initial experience with peritonectomy and intra-peritoneal chemotherapy infusion.
  • INTRODUCTION: Patients diagnosed with peritoneal carcinomatous usually survive for less than 6 months.
  • (1) a demonstrated absence of extra-peritoneal and hepatic spread, (2) fitness of the patient and ability to tolerate cytoreductive surgery and intra-operative chemotherapy, and (3) the presence of a primary tumor originating form the gastro-intestinal tract (colonic, appendiceal, and gastric primaries).
  • CONCLUSIONS: This article describes our initial experience with peritonectomy and intra-operative, intra-peritoneal chemotherapy infusion.
  • With appropriate patient selection, cytoreductive surgery with the infusion of intra-operative chemotherapy can be considered to be a therapeutic option for some patients with diffuse peritoneal metastases, and good disease-free and overall survival can be achieved with minimal morbidity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Peritoneum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2006 Dec;30(12):2087-8 [17103094.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):208-12 [11856136.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):387-92 [15070598.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):20-6 [14718269.001]
  • [Cites] Am Surg. 2000 Jun;66(6):561-8 [10888132.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):65-73 [11237495.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • (PMID = 17006612.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Imamura H, Kishimoto T, Kawabata R, Furukawa H, Fukunaga M, Ohzato H, Miyanishi K, Yamamoto T, Miwa H: [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2490-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection].
  • The patient was a 51-year-old female, who underwent radical surgery for cancer of remnant stomach in May 2006 (f-T4N0M0P0H0CY0, por 2, Stage IIIA, Cur B).
  • Bilateral ovarian resection was performed in March 2009 for bilateral ovarian metastasis, so called "Krukenberg tumor" with peritoneal dissemination detected with CT scan after one-year adjuvant chemotherapy with S-1 (80 mg/m2, 4 weeks on and 2 weeks off).
  • As of June 2010, she is alive and maintain her status quo after 6 courses of S-1 plus CDDP combination therapy (S-1 80 mg/m2, 3 weeks on, CDDP 60 mg/m2, started at day 8, ended 35 days later) followed by S-1 for residual peritoneal dissemination detected at operation.
  • In ovary metastasis of gastric cancer, even if accompanied by peritoneum metastasis, ovarian resection as a reduction surgery followed by chemotherapy may improve survival.
  • [MeSH-major] Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224616.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H: Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res; 2007 Apr 15;67(8):3809-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody.
  • Optical probes that yield high target-to-background ratios are necessary to detect microfoci of cancer that would otherwise escape detection with white light imaging.
  • Following this, a second agent, neutravidin-BODIPY-FL fluorescent conjugate, is given and binds to the previously targeted antibody, resulting in an approximately 10-fold amplification of the optical fluorescence signal, leading to high tumor-to-background ratios.
  • Spectral fluorescence imaging was done in a mouse model of peritoneal metastasis using a HER1-overexpressing cell line (A431) after pretargeting with biotinylated cetuximab and 3 h after administration of neutravidin-conjugated BODIPY-FL.
  • Both aggregated tumors as well as small cancer implants were clearly visualized in vivo.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Avidin / metabolism. Fluorescent Dyes / metabolism. Immunoconjugates / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440095.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Boron Compounds; 0 / Fluorescent Dyes; 0 / Immunoconjugates; 0 / neutravidin; 1405-69-2 / Avidin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


46. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • A 66-year-old woman (156 cm, 58 kg) underwent sigmoid colectomy for cancer.
  • She was found to have simultaneous liver and peritoneal metastases at operation, which had not been detected with CT examination before operation.
  • After operation, CT showed multiple liver metastasis and a high level of CEA and CA19-9 .
  • After 2 courses, tumor sizes of liver metastases and the level of tumor markers became reduced.
  • The current case suggested that the administration of TS-1 and CPT-11 may have a potent therapeutic efficacy in advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


47. Katoh H, Yamashita K, Kokuba Y, Satoh T, Ozawa H, Hatate K, Ihara A, Nakamura T, Onosato W, Watanabe M: Surgical resection of stage IV colorectal cancer and prognosis. World J Surg; 2008 Jun;32(6):1130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of stage IV colorectal cancer and prognosis.
  • BACKGROUND: Colorectal cancer (CRC) harbors accumulated genetic alterations with cancer progression, which results in uncontrollable disease.
  • To regulate the most malignant CRC, we have to know the most dismal phenotype of stage IV disease.
  • Clinical variables were tested for their relationship to survival in a multivariate prognostic analysis and revealed the interaction of the prognostic factors.
  • RESULTS: In stage IV CRC with noncurable resection, the most robust univariate predictors for poor prognosis were preoperative high value of CA19-9, peritoneal dissemination, depth of invasion, age, extent of liver metastases, pathologic lymph node metastasis status, and gender as tumor factors, and postoperative therapy, perioperative transfusion, and lymph node dissection extent as treatment factors.
  • Among these factors, postoperative therapy (p < 0.0001), perioperative transfusion (0.0002), CA19-9 (0.001), extent of liver metastases (0.004), and peritoneal dissemination (0.02) were identified as independent prognostic factors by multivariate analysis.
  • Interestingly, among the independent prognostic factors, treatment factors did not depend upon tumor factors and the combination of the three tumor factors (CA19-9, extent of liver metastases, and peritoneal dissemination) can clearly classify the patients into the definite prognostic groups.
  • CONCLUSION: Our results suggested that the most dismal CRC harbors three definite vectors that may represent the strongest phenotype of putative systemic immune (CA19-9), distant metastasis (extent of liver metastases), and local progression (peritoneal dissemination).
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jul;228(1):59-63 [9671067.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Arch Biochem Biophys. 2004 Jun 15;426(2):122-31 [15158662.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):149-55 [16488536.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):160-4 [11941943.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1377-83 [16619547.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):725-8 [10952775.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):181-7 [12668282.001]
  • [Cites] Med Hypotheses. 2001 Sep;57(3):337-43 [11516226.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):6-11 [16368485.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Sci. 2004 May;95(5):377-84 [15132763.001]
  • [Cites] J Surg Oncol. 2000 Nov;75(3):165-71 [11088047.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3409-18 [16585162.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6127-32 [16144911.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):962-6 [12963652.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):580-5 [15103491.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):325-51 [1423821.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):161-7 [11870500.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1251-5 [15865074.001]
  • [Cites] Lancet. 1995 Jul 8;346(8967):115 [7603185.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Nat Med. 2004 Aug;10 (8):789-99 [15286780.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4597-603 [14673048.001]
  • (PMID = 18340483.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


48. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res; 2006 Feb 15;66(4):2181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
  • Peritoneal carcinomatosis is a frequent cause of death in patients with advanced gastric carcinoma.
  • Because chemokines are now considered to play an important role in the metastasis of various malignancies, we hypothesized that they may be involved in the development of peritoneal carcinomatosis by gastric carcinoma.
  • Human gastric carcinoma cell lines, which were all highly efficient in generating malignant ascites in nude mice upon i.p. inoculation, selectively expressed CXCR4 mRNA and protein.
  • Malignant ascitic fluids from patients with peritoneal carcinomatosis contained high concentrations of CXCL12 (4.67 ng/mL).
  • Moreover, immunohistochemical analysis showed that 22 of 33 primary gastric tumors with peritoneal metastasis were positive for CXCR4 expression (67%), whereas only 4 of 16 with other distant metastasis were positive (25%).
  • Notably, 22 of 26 CXCR4-expressing primary tumors developed peritoneal metastases (85%).
  • CXCR4 positivity of primary gastric carcinomas significantly correlated with the development of peritoneal carcinomatosis (P < 0.001).
  • Collectively, our results strongly suggest that the CXCR4/CXC12 axis plays an important role in the development of peritoneal carcinomatosis from gastric carcinoma.
  • Thus, CXCR4 may be a potential therapeutic target for peritoneal carcinomatosis of gastric carcinoma.
  • [MeSH-major] Carcinoma / secondary. Chemokines, CXC / physiology. Peritoneal Neoplasms / secondary. Receptors, CXCR4 / physiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Ascites / metabolism. Ascites / prevention & control. Cell Line, Tumor. Chemokine CXCL12. Female. Heterocyclic Compounds / pharmacology. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2006 Apr 1;66(7):3957
  • (PMID = 16489019.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 155148-31-5 / JM 3100
  •  go-up   go-down


49. Ando Y, Tsunoda T, Beck Y, Takayama T, Tahara H: Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case. Surg Today; 2005;35(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
  • However, recent reports from Europe have described the effects of imatinib against metastatic GIST.
  • We herein report the case of a Japanese patient treated with imatinib for advanced GIST.
  • Imatinib at 400 mg daily was given to an adult with multiple liver and peritoneal metastases 17 months after undergoing a GIST resection.
  • Our results are consistent with previous reports that show imatinib to be effective for the treatment of metastatic GIST, and also suggest that imatinib at 400 mg daily for more than 7 months is well tolerated in Japanese adults.
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Liver Neoplasms / secondary. Male. Middle Aged. Peritoneal Neoplasms / secondary. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674500.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


50. Kobayashi T, Adachi S, Matsuda Y, Tominaga S: A case of metastatic lobular breast carcinoma with detection of the primary tumor after ten years. Breast Cancer; 2007;14(3):333-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic lobular breast carcinoma with detection of the primary tumor after ten years.
  • Lobular carcinoma of the breast is known to metastasize to unusual sites such as the gastrointestinal tract, peritoneum, and gynecologic organs.
  • We report a patient with intraperitoneal metastases from lobular carcinoma who was originally treated for an unknown primary cancer.
  • Ten years later, a tumor was found in her left breast and the diagnosis was changed to peritoneal metastases from invasive lobular carcinoma.
  • Immunohistochemistry revealed that the metastases were high molecular weight cytokeratin (CK34betaE12) and estrogen receptor-positive, but were E-cadherin-negative.
  • These results assisted in diagnosis.
  • Surgeons should be aware of the characteristics of metastasis lobular carcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Duodenal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Metastasis


51. Tohma T, Yamamoto Y, Seki Y, Takaishi S, Sakuma Y, Funami Y, Tobita K: Weekly paclitaxel therapy is effective for gastric adenosquamous carcinoma: a case report. Hepatogastroenterology; 2009 Mar-Apr;56(90):568-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On endoscopy, a type 3 cancer from the lower body of the stomach to the antrum was found, and abdominal CT scan demonstrated multiple liver metastases and peritoneal dissemination.
  • On, pathological examination, a diagnosis of adenosquamous carcinoma was confirmed, and lymph node metastases around the perigastric areas were found.
  • After two courses of chemotherapy, his liver metastases were found to have progressed, and paclitaxel was given at a weekly dose of 80 mg/m2 for 3 weeks, followed by a one-week rest.
  • The carcinoembryonic antigen level decreased remarkably, and the liver metastases had decreased on CT.
  • Thus, extensive chemotherapy for the liver metastases improved the patient's prognosis, while maintaining his quality of life.
  • [MeSH-minor] Aged. Gastroscopy. Humans. Lymphatic Metastasis. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579645.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


52. Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, Curley SA: High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg; 2007 Jun;193(6):702-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Preoperative helical HRCT (2 contrast phases, rapid intravenous contrast bolus, 2.5-mm section thickness) for 32 consecutive patients who underwent laparotomy for the diagnosis of hilar cholangiocarcinoma from 2000 to 2005 were reviewed by a hepatobiliary radiologist.
  • RESULTS: Fourteen of the 32 (44%) study patients were unresectable (extension along bile duct, 4; peritoneal metastases, 4; vascular encasement, 3; noncontiguous liver metastases, 2; N2 lymphadenopathy, 1).
  • In the 3 cases in which HRCT predicted resectability and the patient was unresectable, subcentimeter peritoneal disease, a subcentimeter liver metastasis, and distal bile duct involvement were responsible factors.
  • Individual radiographic findings that best predicted unresectability were peritoneal spread (P = .015) and hepatic artery (P = .006) or portal vein (P = .002) involvement.
  • Identification of specific radiographic features, in particular major vascular involvement and peritoneal abnormalities, is now used by our group to avoid unnecessary laparotomy.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17512280.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Lu Z, Wang J, Wientjes MG, Au JL: Intraperitoneal therapy for peritoneal cancer. Future Oncol; 2010 Oct;6(10):1625-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal therapy for peritoneal cancer.
  • Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA.
  • Peritoneal metastases are common owing to locoregional spread and distant metastases of extraperitoneal cancers.
  • A logical treatment is intraperitoneal therapy, as multiple studies have shown significant targeting advantage for this treatment, including significant survival benefits in stage III, surgically debulked ovarian cancer patients.
  • This article provides an overview on the background of peritoneal metastasis, clinical research on intraperitoneal therapy, the pharmacokinetic basis of drug delivery in intraperitoneal therapy and our development of drug-loaded tumor-penetrating microparticles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):277-82 [9516911.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):139-43 [9516962.001]
  • [Cites] Gynecol Oncol. 1998 Mar;68(3):267-73 [9570979.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):265-70 [9641228.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2837-42 [9713471.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):347-54 [9742917.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Aug;290(2):871-80 [10411604.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3776-82 [10446995.001]
  • [Cites] Ann N Y Acad Sci. 1956 Mar 14;63(5):915-28 [13314442.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):988-94 [16461779.001]
  • [Cites] J Biomed Mater Res A. 2006 May;77(2):351-61 [16425240.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3 [16611959.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):391-6 [16626792.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):128-33 [17072675.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):509-14 [17096054.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):437-43 [17264340.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):80-8 [17420296.001]
  • [Cites] Pharm Res. 2007 Sep;24(9):1691-701 [17447121.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] Anaesthesia. 2008 Apr;63(4):389-95 [18336490.001]
  • [Cites] Pharm Res. 2008 Jul;25(7):1500-10 [18369709.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):673-82 [18780831.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Probl Cancer. 2009 May-Jun;33(3):142-53 [19647613.001]
  • [Cites] Drugs Today (Barc). 2009 Aug;45(8):589-97 [19927225.001]
  • [Cites] MAbs. 2010 Mar-Apr;2(2):129-36 [20190561.001]
  • [Cites] J Control Release. 2002 Jan 17;78(1-3):81-95 [11772451.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):365-74 [11908929.001]
  • [Cites] Pharm Res. 2002 Apr;19(4):411-7 [12033372.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):26-33 [12511145.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):363-9 [12538489.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):678-85 [12576435.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1337-50 [14567626.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):755-69, xiv [14567029.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901 [14676112.001]
  • [Cites] Front Biosci. 1997 Jan 1;2:g8-10 [9159259.001]
  • [Cites] J Surg Oncol. 2004 Oct 1;88(1):39-43 [15384086.001]
  • [Cites] Cancer Res. 1972 Aug;32(8):1663-6 [5044130.001]
  • [Cites] Radiology. 1973 Jun;107(3):577-83 [4702536.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):567-72 [7471076.001]
  • [Cites] Biomaterials. 1981 Oct;2(4):201-14 [7034798.001]
  • [Cites] Invest New Drugs. 2001 May;19(2):113-23 [11392446.001]
  • [Cites] Curr Opin Chem Biol. 2001 Aug;5(4):447-51 [11470609.001]
  • [Cites] Eur Radiol. 2001;11(11):2195-206 [11702160.001]
  • [Cites] AAPS PharmSci. 2001;3(2):E15 [11741266.001]
  • [Cites] J Pharmacokinet Biopharm. 1994 Jun;22(3):183-205 [7884649.001]
  • [Cites] J Biomater Sci Polym Ed. 1995;6(9):775-95 [7772566.001]
  • [Cites] J Intraven Nurs. 1995 Jul-Aug;18(4):170-6 [7629637.001]
  • [Cites] Cancer Res. 1983 Dec;43(12 Pt 1):5789-91 [6196107.001]
  • [Cites] Am J Physiol. 1984 Apr;246(4 Pt 2):R597-607 [6720931.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):498-504 [6547166.001]
  • [Cites] Ann Intern Med. 1984 Jul;101(1):14-8 [6732077.001]
  • [Cites] Am J Physiol. 1985 Jan;248(1 Pt 2):H26-32 [3155917.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 2):F413-24 [3976900.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 2):F425-35 [3919596.001]
  • [Cites] Tumori. 1985 Feb 28;71(1):63-8 [3984048.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):43-6 [4048975.001]
  • [Cites] J Pharm Sci. 1985 Sep;74(9):915-21 [4067845.001]
  • [Cites] J Biomed Mater Res. 1985 Mar;19(3):349-65 [4077887.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1984;1(1):39-90 [6400195.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1712-6 [3815369.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Semin Oncol. 1988 Jun;15(3 Suppl 4):27-31 [3134695.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5874-7 [3167842.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Semin Oncol. 1989 Aug;16(4 Suppl 6):83-97 [2669141.001]
  • [Cites] Yale J Biol Med. 1989 Jul-Aug;62(4):393-403 [2688324.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):389-94 [2311166.001]
  • [Cites] Eur J Gynaecol Oncol. 1990;11(1):19-22 [2347331.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5790-4 [2118420.001]
  • [Cites] Anticancer Drug Des. 1990 Nov;5(4):359-69 [2127181.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2041-6 [2009523.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):135-40 [2081919.001]
  • [Cites] Pharm Res. 1991 Feb;8(2):168-73 [1902562.001]
  • [Cites] J Appl Physiol (1985). 1991 Apr;70(4):1544-9 [2055834.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4347-54 [1907883.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5144-52 [1913640.001]
  • [Cites] Acta Anat (Basel). 1991;141(1):26-30 [1835238.001]
  • [Cites] Pharm Res. 1991 Oct;8(10):1286-91 [1839060.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(3):235-7 [1548290.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(6):480-4 [1568292.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Res Immunol. 1992 Jun;143(5):557-63; discussion 581 [1439138.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3314-20 [8324743.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(4):255-62 [8324866.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):100-4 [8349150.001]
  • [Cites] Med Device Technol. 1990 Jan-Feb;1(1):15-21 [10148171.001]
  • [Cites] Hepatogastroenterology. 1993 Oct;40(5):430-2 [8270231.001]
  • [Cites] Proc Natl Sci Counc Repub China B. 1993 Jul;17(3):103-5 [8290652.001]
  • [Cites] Br J Cancer. 1994 Feb;69(2):235-41 [8297720.001]
  • [Cites] Science. 1994 Mar 25;263(5154):1715-20 [8134835.001]
  • [Cites] Cancer Surv. 1993;17:105-22 [8137338.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1693-8 [7512437.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):374-8 [8015074.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Aug;31(3):239-46 [10532198.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2403-11 [10561303.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Gynecol Oncol. 2000 Feb;76(2):157-62 [10637064.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5163-7 [10697528.001]
  • [Cites] Eur J Surg Oncol. 2000 Sep;26(6):630-2 [11034822.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):1035-42 [11181938.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):597-604 [11309436.001]
  • [Cites] Bioconjug Chem. 1995 Jul-Aug;6(4):332-51 [7578352.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1995;12(1):1-99 [8521523.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):539-46 [8612307.001]
  • [Cites] Semin Surg Oncol. 1996 Jul-Aug;12(4):267-78 [8829286.001]
  • [Cites] Cancer Treat Res. 1996;81:15-30 [8834572.001]
  • [Cites] Cancer Treat Res. 1996;81:51-61 [8834575.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1392-6 [8912534.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):265-72 [8947523.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Anticancer Drugs. 1997 Feb;8(2):182-8 [9073314.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;41(1):69-74 [9443616.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):130-8 [9499187.001]
  • (PMID = 21062160.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA049816; United States / NCI NIH HHS / CA / R01 CA123159; United States / NCI NIH HHS / CA / R43CA134047; United States / NCI NIH HHS / CA / R01 CA123159-02; United States / NCI NIH HHS / CA / R44CA103133; United States / PHS HHS / / R0ICA123159; United States / NCI NIH HHS / CA / R44 CA103133; United States / NCI NIH HHS / CA / R43CA103133; United States / NCI NIH HHS / CA / CA103133-04; United States / NCI NIH HHS / CA / CA049816-11; United States / NCI NIH HHS / CA / CA103133-01; United States / NCI NIH HHS / CA / CA134047-02; United States / NCI NIH HHS / CA / CA123159-02; United States / NCI NIH HHS / CA / R43 CA134047; United States / NCI NIH HHS / CA / R43 CA134047-02; United States / NCI NIH HHS / CA / R43 CA103133; United States / NCI NIH HHS / CA / R37CA49816; United States / NCI NIH HHS / CA / R44 CA103133-04; United States / NCI NIH HHS / CA / R37 CA049816-11; United States / NCI NIH HHS / CA / R43 CA103133-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers
  • [Other-IDs] NLM/ NIHMS269306; NLM/ PMC3076138
  •  go-up   go-down


54. Fujii Y, Nakazawa K, Yoneto T, Shuzui Y: [A case of peritoneal dissemination caused by recurrent hilar cholangiocarcinoma treated with intraperitoneal infusion of cisplatin (CDDP) and systemic chemotherapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal dissemination caused by recurrent hilar cholangiocarcinoma treated with intraperitoneal infusion of cisplatin (CDDP) and systemic chemotherapy].
  • From surgery, it was diagnosed as peritoneal metastases of the cholangiocarcinoma, and an intraperitoneal infusion port was placed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Humans. Infusions, Parenteral. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633269.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • Free cancer cells might induce or indicate an early peritoneal seeding with a subsequent peritoneal metastasis.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • METHODS: Inside a period from April 2000, and April 2004, the total of 100 patients underwent intraoperative peritoneal lavage for cytological examination.
  • The cytological findings were defined as positive or negative according to the presence of cancer cells.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • RESULTS: Free cancer cells were found in 24 (24%) of the patients, while in 76 (76%) of them cytological findings were negative.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • Free cancer cells were statistically more frequently (p < or = 0.05) detected in the patients with lymph nodes metastases comparing to the patients with out lymph nodes involvement.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • CONCLUSION: Peritoneal lavage cytology was shown to be a useful tool for the detection of the group of patients with greatest risk of peritoneal dissemination.
  • The frequency of positive cytological findings was highly associated with the diameter of the tumor and the cancer invasion of serosa.
  • Cytological examination of peritoneal lavage fluid improved the accuracy of staging and selection of patients who might have benefit from neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytodiagnosis. Female. Gastrectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Lavage. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


56. Bai F, Liang J, Wang J, Shi Y, Zhang K, Liang S, Hong L, Zhai H, Lu Y, Han Y, Yin F, Wu K, Fan D: Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer. J Mol Med (Berl); 2007 Feb;85(2):169-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.
  • Peritoneal dissemination in gastric cancer is the most frequent cause of the noncurative resection and recurrence after curative resection.
  • We, therefore, evaluated the feasibility of a peptide, which was obtained by screening a random phage display library, in the treatment of peritoneal metastases of gastric cancer.
  • In this study, a novel cell line, GC9811-P, with a high potential peritoneal metastasis of gastric cancer derived from its parental cell line, GC9811, was established.
  • The isolated phage-displaying peptide, SMSIASPYIALE (named peptide PIII), was obtained after four rounds of selection, showing a tendency to preferentially bind to GC9811-P cells compared with a panel of other gastric cancer cell lines, and preferentially accumulate in peritoneal metastasis tumor tissue in comparison with control organs, peritoneum, liver, pancreas, spleen, lung, and kidney.
  • Furthermore, a highly reproducible animal experimental model of gastric cancer with peritoneal dissemination was established in nude mice by injecting a suspension of the cell line into the gastric wall of nude mice.
  • Animals intraperitoneally treated with peptide PIII in this model or another animal model of gastric cancer with peritoneal dissemination established using MKN45 cells showed suppressed tumor metastasis to peritoneum and significantly prolonged survival.
  • In conclusion, the selected peptide PIII was a biologically active peptide and could effectively inhibit peritoneal dissemination of gastric cancer.
  • [MeSH-major] Neoplasm Metastasis / drug therapy. Peptides / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Mice, Nude. Neoplasm Invasiveness / prevention & control. Neoplasm Transplantation. Peptide Library. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49301-7 [14506238.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1504-8 [11677996.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Oct;126(10):595-600 [11043397.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1232-5 [15492500.001]
  • [Cites] Pancreatology. 2005;5(4-5):316-24; discussion 324 [15983443.001]
  • [Cites] Oncology. 2005;69 Suppl 1:1-8 [16210869.001]
  • [Cites] J Mol Biol. 2000 Sep 1;301(5):1149-61 [10966812.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1723-6 [15553695.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):601-9 [10228868.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Nat Biotechnol. 2000 Jan;18(1):33-7 [10625387.001]
  • [Cites] Circulation. 2000 Jul 11;102(2):231-7 [10889136.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2651-61 [15814646.001]
  • [Cites] Curr Opin Biotechnol. 2000 Oct;11(5):461-6 [11024364.001]
  • [Cites] Br J Surg. 2000 Mar;87(3):353-7 [10718807.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 24;341(4):964-72 [16458253.001]
  • [Cites] Trends Biotechnol. 2001 Jan;19(1):21-8 [11146099.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6551-6 [11118031.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 26;1475(3):369-76 [10913838.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):219-30 [14643452.001]
  • [Cites] EMBO J. 2000 Apr 3;19(7):1525-33 [10747021.001]
  • [Cites] Dig Dis. 2004;22(4):366-73 [15812161.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):809-14 [10854549.001]
  • [Cites] Oncol Rep. 2005 May;13(5):801-5 [15809741.001]
  • [Cites] J Drug Target. 1999 Dec;7(4):249-68 [10682905.001]
  • [Cites] J Cell Biol. 1995 Sep;130(5):1189-96 [7657703.001]
  • [Cites] Prostate. 2001 Jun 1;47(4):239-51 [11398171.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Oct;32(10):1404-9 [16227738.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):450-6 [10667600.001]
  • [Cites] Cancer Detect Prev. 1998;22(2):139-46 [9544434.001]
  • (PMID = 17043801.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  •  go-up   go-down


57. Masellis AM, Sielaff TD, Bender GP: Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol; 2009 Oct;14(5):478-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
  • Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States.
  • We report the case of a 41-year-old woman who was diagnosed with advanced metastatic well-to-moderately differentiated mucinous adenocarcinoma of the pancreas, involving the liver and peritoneal cavity.
  • Complete response of multiple liver and peritoneal metastases and reduction in size with increasing calcification of the pancreatic mass occurred in this patient after 18 months of treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2007 Aug;34(4):347-53 [17674963.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75 [17440727.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66 [17285317.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Expert Opin Pharmacother. 2007 Nov;8(16):2719-27 [17956194.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):525-33 [17577216.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:20-5 [18336394.001]
  • (PMID = 19856062.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 130-nm albumin-bound paclitaxel; 0 / Albumins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Sakamoto H, Amikura K, Tanaka Y, Nishimura Y, Kawashima Y, Yatsuoka T, Yamagata Y, Yamaura T, Yokoyama Y, Akiyama H, Nakajima T: [Successful treatment of multiple pulmonary and peritoneal recurrence of hepatocellular carcinoma with bronchial artery infusion therapy and PEIT followed by surgery--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of multiple pulmonary and peritoneal recurrence of hepatocellular carcinoma with bronchial artery infusion therapy and PEIT followed by surgery--a case report].
  • An 80-year-old male presented with multiple pulmonary and peritoneal metastases 4 months after right heimihepatectomy for ruptured HCC.
  • Peritoneal tumor was treated by arterial infusion of SMANCS, followed by percutaneous injection of absolute ethanol, which ended in surgical removal in 28-postoperative month due to abscess formation.
  • He had been well until right adrenal and left pulmonary metastases appeared.
  • Resection of both metastases was carried out in 39-post hepatectomy month.
  • Recurrent left pulmonary metastasis was treated with two sessions of bronchial artery infusion with no effect this time.
  • Eventually pulmonary metastasis recurred and tumor thrombus reached the left atrium 58 months after hepatectomy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Ethanol / administration & dosage. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224680.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Maleic Anhydrides; 0 / Polystyrenes; 0 / poly(maleic acid-styrene)neocarzinostatin; 3K9958V90M / Ethanol; 50SG953SK6 / Mitomycin; 9014-02-2 / Zinostatin
  •  go-up   go-down


59. Sugie T, Nagai T, Ohgaki K: [Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery]. Gan To Kagaku Ryoho; 2007 May;34(5):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery].
  • Two patients with advanced gastric cancer who underwent gastrectomy and pathological examination were both diagnosed as having Stage IV gastric cancer with distant lymph-node metastases and peritoneal dissemination, respectively.
  • These results suggest that combination therapy with S-1 and low-dose CDDP is effective against advanced gastric cancer.
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Neoplasm Staging. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496454.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J, Cai S, Ma J: Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun; 2006 Sep 15;348(1):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
  • High expression of PRL-3, a protein tyrosine phosphatase, is proved to be associated with lymph node metastasis in gastric carcinoma from previous studies.
  • In this paper, we examined the relationship between PRL-3 expression and peritoneal metastasis in gastric carcinoma.
  • We applied the artificial miRNA (pCMV-PRL3miRNA), which is based on the murine miR-155 sequence, to efficiently silence the target gene expression of PRL-3 in SGC7901 gastric cancer cells at both mRNA and protein levels.
  • In vivo, PRL-3 knockdown effectively suppressed the growth of peritoneal metastases and improved the prognosis in nude mice.
  • Therefore, we concluded that artificial miRNA can depress the expression of PRL-3, and that PRL-3 might be a potential therapeutic target for gastric cancer peritoneal metastasis.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / genetics. Cell Proliferation. Humans. Mice. MicroRNAs. Neoplasm Transplantation. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / secondary. Plasmids

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875667.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / MicroRNAs; 0 / Ptp4a3 protein, mouse; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


61. Agrawal S, Sonawane RN, Behari A, Kumar A, Sikora SS, Saxena R, Kapoor VK: Laparoscopic staging in gallbladder cancer. Dig Surg; 2005;22(6):440-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic staging in gallbladder cancer.
  • PURPOSE: Laparoscopy is beneficial in the staging of pancreatic and upper gastrointestinal malignancies but its role in gallbladder cancer has not been investigated.
  • We evaluated the role of laparoscopy in the staging of gallbladder cancer.
  • METHODS: From 1989 through 2001, 91 patients with gallbladder cancer, without any evidence of metastatic disease on imaging (ultrasound and/or computed tomographic scan), underwent staging laparoscopy.
  • Peritoneal and surface liver metastases were looked for and assessment of local spread was done if possible.
  • RESULTS: At laparoscopy, 34 (37%) patients had disseminated disease in the form of liver and/or peritoneal deposits; no further surgery was performed in 29 of these patients while 5 patients underwent surgical bypass procedures.
  • Liver metastases were missed at laparoscopy in 2 patients and were subsequently found at laparotomy.
  • Of the 51 patients without metastatic disease, who underwent laparotomy, 11 were found to have nonresectable locally advanced disease while 1 had liver metastases, which were missed at laparoscopy; 7 underwent bypass procedures only; 21 underwent simple cholecystectomy and extended cholecystectomy was done in 11 patients.
  • CONCLUSIONS: Staging laparoscopy in patients with gallbladder cancer detected liver and peritoneal metastases that were missed on imaging.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Laparoscopy. Neoplasm Staging / methods
  • [MeSH-minor] Cholecystectomy. Female. Humans. Laparotomy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Metastasis. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16479113.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Miyagi M, Aoyagi K, Kato S, Shirouzu K: The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol; 2007 Feb;12(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer.
  • BACKGROUND: It has become clear in recent years that peritoneal metastasis takes place as the result of a multistep process involving attachment, invasion, proliferation, and angiogenesis.
  • The aim of the present study was to evaluate the suppressive effect of tissue inhibitor of metalloproteinase-1 (TIMP-1) gene transfer on peritoneal dissemination.
  • METHODS: We established a high-potential peritoneal metastasis cell line (MKN-45P), using the gastric cancer cell line MKN-45, and developed a peritoneal metastasis model in nude mice.
  • The TIMP-1 gene was transferred to MKN-45 or MKN-45P by adenoviral transfection, and we performed an in vitro invasion assay and an in vivo study, using the peritoneal metastasis model.
  • RESULTS: The in vitro invasion assay showed that the number of invasive cells was significantly reduced in the TIMP-1 transfected group compared with that in the non-virus group and the Lac-Z transfected group, Moreover, the in vivo studies showed that the number and the weight of the peritoneal nodes in the TIMP-1 transfected group were significantly less than those in the Lac-Z transfected group, and less than those in the non-viral group.
  • CONCLUSION: TIMP-1 demonstrated an inhibitory effect on angiogenesis, and may be worthwhile investigating for use as a future therapy for peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoviridae. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Genetic Vectors. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / prevention & control. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):767-74 [12639219.001]
  • [Cites] J Cell Physiol. 1994 Jul;160(1):194-202 [7517405.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):700-10 [15906450.001]
  • [Cites] Gut. 1998 Dec;43(6):791-7 [9824606.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1676-80 [8608561.001]
  • [Cites] J Biol Chem. 1996 Sep 27;271(39):23938-45 [8798626.001]
  • [Cites] J Cell Biol. 1992 Aug;118(3):727-39 [1639854.001]
  • [Cites] Gastric Cancer. 2000 Sep 29;3(2):63-70 [11984713.001]
  • [Cites] J Natl Cancer Inst. 1992 Jul 1;84(13):1017-22 [1318976.001]
  • [Cites] Mol Cancer Res. 2006 Mar;4(3):209-20 [16547158.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 4;82(7):589-95 [2156082.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17 [15000152.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):111-20 [11235986.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):77-81 [9288970.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):115-20 [15583811.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):299-304 [8158685.001]
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Expert Rev Mol Med. 2003 Sep 22;5(23):1-39 [14585170.001]
  • [Cites] Invasion Metastasis. 1989;9(6):391-405 [2689386.001]
  • [Cites] FEBS Lett. 1992 Feb 17;298(1):29-32 [1544418.001]
  • [Cites] Biochemistry. 1991 Aug 20;30(33):8097-102 [1868085.001]
  • [Cites] Science. 1989 Feb 17;243(4893):947-50 [2465572.001]
  • [Cites] Int J Oncol. 1996 Apr;8(4):795-802 [21544429.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1397-402 [8443819.001]
  • [Cites] Bioessays. 1992 Jul;14(7):455-63 [1445287.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5539-45 [3416307.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6267-75 [10626822.001]
  • [Cites] Eur J Biochem. 1997 Feb 15;244(1):81-8 [9063449.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 [15588763.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] J Vet Med Sci. 2006 Feb;68(2):105-11 [16520530.001]
  • [Cites] Surg Today. 2000;30(7):614-21 [10930227.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):137-44 [8744792.001]
  • [Cites] J Clin Invest. 1998 Dec 1;102(11):2002-10 [9835626.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):701-8 [1732058.001]
  • [Cites] EMBO J. 1995 Mar 1;14(5):908-17 [7534227.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):23-30 [16501233.001]
  • (PMID = 17380436.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


63. Herman P, Machado MA, Montagnini AL, D'Albuquerque LA, Saad WA, Machado MC: Selected patients with metastatic melanoma may benefit from liver resection. World J Surg; 2007 Jan;31(1):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selected patients with metastatic melanoma may benefit from liver resection.
  • BACKGROUND: In the last few years there has been expanding use of hepatic resection for non-colorectal metastases.
  • The purpose of this study is to evaluate the experience of liver resection for patients with metastatic melanoma.
  • METHODS: Eighteen patients with metastatic melanoma were explored for possible surgical resection.
  • RESULTS: Liver resection was performed in 10 patients; 8 out of 18 presented with irresectable tumors and/or peritoneal metastases and were not operated.
  • CONCLUSIONS: Resection of liver metastases from melanoma in a selected group of patients may increase survival.
  • [MeSH-major] Eye Neoplasms / pathology. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Melanoma / secondary. Patient Selection. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2006 Mar;141(3):284-8 [16549694.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):38-43 [12831922.001]
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):127-30 [9591028.001]
  • [Cites] Am J Surg. 1978 Mar;135(3):389-94 [626320.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):950-5 [11485537.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):459-61 [10228842.001]
  • [Cites] Liver Transpl. 2000 Jan;6(1):97-101 [10648585.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):762-70 [12374659.001]
  • [Cites] Surgery. 1991 Feb;109 (2):127-31 [1992544.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):122-9 [14692032.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):479-90 [12394190.001]
  • [Cites] Arch Surg. 1988 Sep;123(9):1091-5 [3415459.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):155-60 [15075909.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1532-6 [11775186.001]
  • [Cites] Int Surg. 1982 Jul-Sep;67(3):257-60 [7160983.001]
  • [Cites] J Am Coll Surg. 1998 Nov;187(5):487-93 [9809564.001]
  • [Cites] Semin Surg Oncol. 1992 Nov-Dec;8(6):381-91 [1439449.001]
  • (PMID = 17171491.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


64. Knigge U, Hansen CP: [Appendiceal carcinoid tumors and goblet cell carcinoids]. Ugeskr Laeger; 2010 May 31;172(22):1678-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases to regional nodes are seen in 10% of CATs larger than two cm.
  • Ovarian or peritoneal metastases are seen in 20% of all GCCATs.
  • Non-resectable GCCATs are treated like colo-rectal cancer.
  • Patients with CAT larger than two cm, involvement of mesoappendix or metastases and all GCCAT should be followed life-long.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20525467.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


65. Hattangadi JA, Hong TS, Yeap BY, Mamon HJ: Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer; 2009 Aug 15;115(16):3640-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although adjuvant chemoradiation is used commonly in the United States for the treatment of resected pancreatic cancer, there is no consensus on the benefit of this therapy, because the results from randomized trials are conflicting.
  • The authors of this report reviewed their experience in a consecutive, unselected series of patients who received adjuvant 5-fluorouracil (5-FU) and radiation therapy (RT) for resected pancreatic adenocarcinoma.
  • Seventy-five patients (87%) had disease recurrence, and the majority recurred with peritoneal metastases (55%) or liver metastases (53%).
  • CONCLUSIONS: The median survival of the current cohort was greater than that of the chemoradiation arms of European Organization for Research and Treatment of Cancer trials and European Study Group for Pancreatic Cancer 1 trials and was comparable to the survival observed on the Gastrointestinal Tumor Study Group chemoradiation arm.
  • Future survival improvements should be directed at reducing peritoneal and liver metastases.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1565-6 [11716876.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):613-23 [9684106.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):489-94 [10521065.001]
  • [Cites] Int J Clin Oncol. 2004 Dec;9(6):451-7 [15616875.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1019-26 [18319412.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1483-7 [11121652.001]
  • (PMID = 19514088.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / P30 CA06516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS511646; NLM/ PMC3808178
  •  go-up   go-down


66. Dasari BV, Loan W, Carey DP: Spilled gallstones mimicking peritoneal metastases. JSLS; 2009 Jan-Mar;13(1):73-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spilled gallstones mimicking peritoneal metastases.
  • CASE REPORT: We report a case of spilled gallstones mimicking peritoneal metastases on radiological investigations; diagnosis was confirmed by diagnostic laparoscopy.
  • When all the stones cannot be retrieved, it should be documented in the patient's medical records to avoid delay in the diagnosis of late complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1441-5 [10789809.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1226-32 [11984670.001]
  • [Cites] Surg Endosc. 2004 Aug;18(8):1200-7 [15457378.001]
  • [Cites] Am J Surg. 2007 Jan;193(1):73-8 [17188092.001]
  • [Cites] Surg Endosc. 1998 Apr;12(4):305-9 [9543518.001]
  • [Cites] Surg Endosc. 1999 Nov;13(11):1099-102 [10556446.001]
  • [Cites] HPB Surg. 1998;11(2):105-8; discuss 108-9 [9893240.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):450-2 [15820459.001]
  • [Cites] J Gastrointest Surg. 1997 Jan-Feb;1(1):85-90; discussion 90-1 [9834334.001]
  • [Cites] Surg Endosc. 1992 Mar-Apr;6(2):84 [1344590.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):564-7 [16447096.001]
  • [Cites] Eur J Surg. 1998 Jun;164(6):425-31 [9696443.001]
  • (PMID = 19366546.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015906
  •  go-up   go-down


67. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB: Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg; 2005 Mar;200(3):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer.
  • BACKGROUND: Identification of extracellular matrix proteins (ECM) associated with tumor cell metastasis may generate targets for future therapy against pancreatic cancer metastases.
  • We hypothesized that comparison of ECM-associated gene expression in primary and metastatic pancreatic tumors would identify ECM proteins associated with pancreatic metastasis.
  • STUDY DESIGN: A clinically relevant model of pancreatic cancer was used to generate RNA from primary and metastatic tumors; it was evaluated by microarray analysis with subsequent cluster analysis.
  • RESULTS: Peritoneal metastases at sites distant from the primary tumor were present in all animals bearing orthotopic tumors.
  • High-density microarray comparison of gene expression in metastases versus primary pancreatic tumors identified a greater than twofold increase in the expression of Cyr61, a secreted matricellular protein that binds to integrins.
  • Reverse transcription polymerase chain reaction confirmed the microarray results, and immunohistochemistry analysis demonstrated increased Cyr61 protein and persistent alpha(v)beta(3) expression in peritioneal metastases.
  • Additionally, immunohistochemistry demonstrated increased collocalization of Cyr61 and alpha(v) in metastases relative to primary tumor.
  • CONCLUSIONS: The ECM protein Cyr61 shows increased expression in metastatic lesions in a clinically relevant model of pancreatic adenocarcinoma.
  • Protein analysis confirms the microarray results and collocalization of Cyr61, and alpha(v) suggests that interaction between Cyr61 and alpha(v)beta(3) promotes formation of peritoneal metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic / genetics. Immediate-Early Proteins / genetics. Intercellular Signaling Peptides and Proteins / genetics. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Animals. Antibodies, Neoplasm / immunology. Cluster Analysis. Cysteine-Rich Protein 61. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Neoplasm Transplantation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737847.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / CYR61 protein, human; 0 / Cyr61 protein, mouse; 0 / Cysteine-Rich Protein 61; 0 / Extracellular Matrix Proteins; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


68. Cribbs RK, Wulkan ML, Heiss KF, Gow KW: Minimally invasive surgery and childhood cancer. Surg Oncol; 2007 Nov;16(3):221-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgery and childhood cancer.
  • Over the last 2 decades, minimally invasive surgery (MIS) has become a significant tool for the diagnosis and treatment of malignant disease in adults.
  • Despite initial reports of port-site metastases and peritoneal spread following laparoscopic resection of colorectal cancer in the 1990s, MIS is now commonly used for many applications in adult surgical oncology, including biopsy and resection of malignant disease in the chest and abdominal cavities, mediastinal and retroperitoneal lymph node dissection, staging of abdominal, pelvic and thoracic malignancies, and management of therapeutic complications.
  • Herein, we review the role of MIS in the diagnosis, staging and treatment of malignant disease in children.
  • We will also evaluate MIS as it applies to the palliation of disease and the management of treatment complications in childhood cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936618.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 63
  •  go-up   go-down


69. Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H: Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol; 2008 Jul;15(7):1959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor diameter as a prognostic factor in patients with gastric cancer.
  • BACKGROUND: The aim of this study was to evaluate the prognostic value of tumor diameter in gastric cancer.
  • Multivariate analysis showed that tumor site, macroscopic appearance, tumor diameter, depth of invasion, and presence of lymph node metastasis independently affected prognosis in all patients.
  • A comparison of clinicopathological factors between stage II and III patients revealed that tumors occupying the entire stomach, ill-defined, undifferentiated, and serosa-penetrating tumors, and peritoneal metastases were far more frequent in patients with larger tumors.
  • CONCLUSIONS: Tumor diameter in gastric cancer is a reliable prognostic factor that might be a candidate for use in the staging system.
  • To improve outcomes for patients with tumors >/=100 mm in diameter, it is necessary to establish therapeutic strategies for peritoneal metastasis, particularly in stage II and III tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Gastrectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369676.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Yoshikawa T, Tsuburaya A, Kobayashi O: [Treatment strategy for primary gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for primary gastric cancer with peritoneal dissemination].
  • Curative resection is considered to be a standard therapy for gastric cancer with localized peritoneal metastases.
  • It is important to evaluate the severity of peritoneal dissemination by diagnostic laparoscopy or laparotomy for decision making.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227737.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


71. Thaler K, Kanneganti S, Khajanchee Y, Wilson C, Swanstrom L, Hansen PD: The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch Surg; 2005 Aug;140(8):727-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis.
  • This study evaluates the effect of staging laparoscopy (SL) using intraoperative ultrasonography (IOUS) on the regional treatment of isolated hepatic colorectal metastasis.
  • PATIENTS: Consecutive patients who have a colorectal metastasis confined to the liver and selected for surgical regional treatment.
  • Staging laparoscopy/IOUS identified surgically untreatable disease in 34 events (25%) because of peritoneal metastases (n = 15), nodal involvement (n = 11), diffuse hepatic disease (n = 5), no identifiable disease (n = 2), and untreatable disease (n = 1).
  • CONCLUSION: In the regional management of isolated colorectal hepatic metastasis, SL/IOUS avoids unnecessary laparotomies and influences definitive surgical intervention in a substantial proportion of patients.
  • [MeSH-major] Colorectal Neoplasms / pathology. Laparoscopy / methods. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103281.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Snyder MJ, Bentley R, Robboy SJ: Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol; 2006 Apr;25(2):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis.
  • However, uterine serous carcinomas (USCs) metastasize frequently to peritoneal surfaces even when only minimally invasive.
  • Primary peritoneal cases and cases with significant ovarian involvement were excluded.
  • Fifty-four of 87 (62%) had extrauterine spread at hysterectomy, most commonly to peritoneal surfaces and sometimes to the pelvic lymph nodes.
  • Eleven of these 54 (20%) patients with metastases lacked both myometrial and LV invasion, and the metastases involved the peritoneal surface more often than the lymph nodes (p<0.001).
  • Another 13 cases also had clusters of tumor within the fallopian tube lumen, and all 16 cases had peritoneal spread (p<0.001).
  • Retrograde transtubal implantation as well LV invasion are two important mechanisms by which USC spreads; all cases with tumor clusters in the fallopian tube lumen had peritoneal spread.
  • This explains the phenomenon whereby patients with serous carcinomas confined to the endometrium and lacking LV invasion have widespread metastases to the peritoneum.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Fallopian Tubes / pathology. Female. Humans. Hysterectomy. Neoplasm Invasiveness. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633065.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Massart C, Lucas C, Rioux-Leclercq N, Fergelot P, Pouvreau-Quillien V, Volatron AC: Importance of the detection method for intact dimeric human chorionic gonadotropin without interference with the free human chorionic gonadotropin beta subunit for pregnancy exclusion before liver transplantation in a woman with cholangiocarcinoma. Clin Chem Lab Med; 2005;43(8):886-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of the detection method for intact dimeric human chorionic gonadotropin without interference with the free human chorionic gonadotropin beta subunit for pregnancy exclusion before liver transplantation in a woman with cholangiocarcinoma.
  • In this work, we compared the performance of several immunoassays for pregnancy exclusion before liver transplantation and in the follow-up of a woman with cholangiocarcinoma.
  • The expression of hCG was also evaluated by immunohistochemistry on sections of intrahepatic cholangiocarcinoma cells and on peritoneal metastases.


74. Bauerschlag DO, Schem C, Tiwari S, Egberts JH, Weigel MT, Kalthoff H, Jonat W, Maass N, Meinhold-Heerlein I: Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res; 2010 Sep;30(9):3355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
  • BACKGROUND: Treatment of ovarian cancer is still challenging especially in recurrent platinum refractory cases.
  • It has been approved for the treatment of recurrent gastro intestinal stroma tumors and metastatic renal cancer.
  • MATERIALS AND METHODS: In this study, sunitinib was tested for its effectiveness as a single agent in an ovarian cancer xenograft mouse model.
  • RESULTS: Sunitinib significantly reduced tumor growth (p=0.0052) and peritoneal metastases, and was associated with a significantly reduced microvessel density count (p<0.001).
  • CONCLUSION: These results suggest that clinical trials are warranted for the evaluation of sunitinib for treatment of patients with recurrent or advanced ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944108.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


75. Tanaka K, Kanamaru T, Yamamoto M: [A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy]. Gan To Kagaku Ryoho; 2006 Jul;33(7):993-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
  • We experienced the case of a 62-year-old woman who obtained long-term survival of three years by TS-1+paclitaxel (PTX) administration for gastric cancer postoperative peritoneal metastases.
  • We first performed total gastrectomy, and the diagnosis was T3N2M0, Stage IIIB.
  • Next, we performed chemotherapy by postoperative 5-FU+cisplatin (CDDP) and met in ambulatory.
  • A bowel movement aberration was found during the course at 3 years postoperatively, and close inspection revealed sigmoid colon stenosis by peritoneal metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835495.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C: State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging; 2007 Dec;18(6):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the-art magnetic resonance imaging of pancreatic cancer.
  • For adenocarcinoma, which is the most common malignant pancreatic tumor, helical CT has been most often used for detection and staging, but it has limitations in the detection of small cancers 2 cm in diameter or less (sensitivity, 63%).
  • Moreover, it is not very accurate in determining nonresectability, because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed.
  • Contrast-enhanced MRI is a problem-solving tool in case of equivocal CT: it helps to differentiate between cancer and focal pancreatitis.
  • Neuroendocrine carcinoma may present with a spectrum of appearances at MRI, but the primary tumor and liver metastases are hypervascular in approximately 70%.
  • We present the imaging features of pancreatic cancer and the important questions in staging, which should be addressed by the radiologist.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Contrast Media. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303400.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


77. Aigner KR, Gailhofer S: Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases. Anticancer Res; 2005 Nov-Dec;25(6C):4407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases.
  • PATIENTS AND METHODS: Two hundred and sixty-five patients with locally advanced or metastasizing (UICC III/IV) pancreatic cancer underwent celiac axis infusion with Mitomycin, Mitoxantrone and Cisplatin combined with degradable starch microspheres in 5 courses and 1 course of isolated hypoxic abdominal perfusion and chemofiltration.
  • The longest actual survival time was ten years in a former unresectable stage IV patient.
  • Peritoneal carcinosis or progression of liver metastases occurred in 18%.
  • Relapses predominantly occurred at the primary site, and progression of distant metastases and peritoneal lesions may be reduced due to isolated abdominal perfusion.
  • [MeSH-minor] Celiac Artery. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Humans. Infusions, Intra-Arterial. Microspheres. Mitomycin / administration & dosage. Mitomycin / adverse effects. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Second-Look Surgery. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334117.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 82643-48-9 / Spherex; 9005-25-8 / Starch; BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


78. Kim JC, Hong HK, Lee KH, Ka IH, Roh SA, Koo KH, Kim HC, Oh ST, Oh SJ, Kim JS, Park KC: Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab')2. J Cancer Res Clin Oncol; 2005 Aug;131(8):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab')2.
  • PURPOSE: In gastric cancer, peritoneal dissemination is the most frequent cause of the noncurative resection and recurrence after curative resection.
  • We therefore evaluated the feasibility of radioimmunoguided surgery (RIGS) in the treatment of peritoneal metastases of gastric cancer and the use of anti-CEA-specific T84.66 F(ab')2 as an efficient immune agent.
  • METHODS: Two human gastric cancer cell lines, MKN45 and RF48, were intraperitoneally xenografted into nude mice, which were later injected with 125I-labeled T84.66 F(ab')2.
  • Peritoneal tumors were localized by RIGS 5 days after antibody injection.
  • RESULTS: We observed 37 peritoneal metastases: 8 invisible (long diameter, <1 mm), 6 small (1- < 5 mm), and 23 large (> or =5 mm) tumors.
  • The accuracy, sensitivity and specificity of RIGS in detecting peritoneal metastasis were 82% (69/84), 76% (28/37), and 87% (41/47), respectively.
  • Mean scores of CEA immunostaining and silver grains in tumors were significantly higher than those in the nontumor-bearing peritoneum (P < 0.001).
  • CONCLUSIONS: 125I-labeled T84.66 F(ab')2 efficiently targeted peritoneally disseminated gastric cancer cells, suggesting that RIGS using this immune agent may accurately detect occult peritoneal metastases in patients with gastric cancer.
  • [MeSH-major] Carcinoembryonic Antigen / immunology. Peritoneal Neoplasms / diagnostic imaging. Peritoneal Neoplasms / surgery. Radioimmunodetection / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12 ):1659-66 [14668592.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):356-61 [11438272.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):367-74 [12115555.001]
  • [Cites] Curr Opin Cell Biol. 1997 Oct;9(5):616-26 [9330864.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):542-7 [11802220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1541-5 [2304917.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):365-74 [11908929.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):1889-94 [8572574.001]
  • [Cites] Ann Surg Oncol. 1997 Jul-Aug;4(5):371-6 [9259962.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1711-9 [10815889.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):687-92 [8425204.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):580-9 [8299079.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):663-70 [15161009.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1113-9 [12945079.001]
  • [Cites] Clin Exp Metastasis. 2004;21(1):39-47 [15065601.001]
  • [Cites] J Pathol. 2001 Apr;193(4):530-7 [11276014.001]
  • [Cites] Int J Rad Appl Instrum B. 1988;15(6):595-603 [3251894.001]
  • [Cites] Protein Eng Des Sel. 2004 Jan;17(1):21-7 [14985534.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):197-202 [14761924.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(2):236-8 [6470030.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3855-63 [11051230.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):465-72 [12884919.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52 [14676105.001]
  • [Cites] Nucl Med Biol. 1996 Aug;23 (6):821-6 [8940726.001]
  • [Cites] Nuklearmedizin. 1995 Feb;34(1):8-14 [7724366.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):965-72 [12918078.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17 ):4825-9 [10987293.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):233-48 [14648781.001]
  • (PMID = 15887029.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Carcinoembryonic Antigen; 0 / Immunoglobulin Fragments; 0 / Iodine Radioisotopes
  •  go-up   go-down


79. Ikarashi S, Akiyama N, Motoyama H, Sasaki S, Ito H, Funakoshi K, Kato T, Arai F: [A case of advanced gastric cancer successfully treated by combination therapy of S-1 and docetaxel]. Gan To Kagaku Ryoho; 2008 Feb;35(2):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer successfully treated by combination therapy of S-1 and docetaxel].
  • A 70-year-old man with gastric cancer of Borrmann type 3, liver metastases and peritoneal dissemination was treated by combination therapy of S-1 and docetaxel (DOC).
  • After 2 courses of treatment, a CT scan revealed improvement of the gastric wall thickness, the eminent decrease of the peritoneal fluid and the reduction of the liver metastasis.
  • A case of an advanced gastric cancer patient successfully treated by combination therapy of S-1 and DOC was reported.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Female. Gastroscopy. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281767.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


80. Sato A, Nakamachi M: [Gastric cancer]. Gan To Kagaku Ryoho; 2009 Feb;36(2):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric cancer].
  • The prognostic significance of histologic type is unclear in patients with gastric cancer.
  • The differentiated type is related to metastasis in the liver and the undifferentiated type to the peritoneum metastasis.
  • CPT-11 and CPT-11+ CDDP combined therapy, which is the second-line therapy, can be expected to be effective in a gastric cancer patient with target lesion like liver metastasis.
  • With paclitaxel and docetaxel, the second-line therapy, the effect is expected in a gastric cancer patient without a target lesion like peritoneal metastasis.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Nap RR, Meinardi JR, van den Berg G, Dullaart RP, de Vries J, Wolffenbuttel BH: [Long-term follow-up is indicated after surgery for a phaeochromocytoma]. Ned Tijdschr Geneeskd; 2006 May 13;150(19):1045-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Langdurige controle aangewezen na chirurgische behandeling wegens een feochromocytoom.
  • In addition to peritoneal metastases confirmed to be caused by malignant phaeochromocytoma he also had a carcinoma of the caecum.
  • The second patient, a 32-year-old woman, complained of headache and palpitations and had liver-enzyme disorders.
  • After a healthy son had been born by caesarian section, she underwent debulking of the large intra-abdominal lymph nodes and of two metastases in the lung.
  • At the last follow-up she was under treatment with radioactive 123I-meta-iodobenzylguanidine (123-MIBG) because of residual metastases.
  • Studies report recurrence ofphaeochromocytoma in 8-20% of cases, and such a recurrence may be either benign or malignant.
  • Factors predictive for recurrence are older age, a malignant primary tumour, tumour weight above 60 g, extra-adrenal origin of the tumour and peroperative tumour spill.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733977.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


82. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, Kenzaki K, Miyoshi T, Kondo K, Bando Y, Ohnishi Y, Tangoku A: Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer; 2009 Aug 15;125(4):952-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
  • A new animal model of esophageal cancer causing tumor colonization of the peritoneal cavity and producing bloody ascites was made by injecting YES-2 cells into the peritoneal cavity of a severe combined immunodeficiency mouse.
  • In this model, 5-fluorouracil inhibited colonization of tumor cells in the peritoneum.
  • The addition of JAE to 5-fluorouracil augmented the suppression of experimental metastasis of the peritoneum.
  • The numbers of peritoneal nodules of more than 2 mm in diameter in mice treated with 5-fluorouracil and JAE were less than those in mice treated with 5-fluorouracil alone or JAE alone.
  • These results suggest that triterpenes, especially JAE, are effective supplements for enhancing the chemotherapeutic effect of 5-fluorouracil on esophageal cancer.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Cell Proliferation / drug effects. Esophageal Neoplasms / drug therapy. Fluorouracil / pharmacology. Peritoneal Neoplasms / drug therapy. Triterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19462449.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Preparations; 0 / Triterpenes; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


83. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H, Yasui W: Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif; 2009 Feb;42(1):110-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV enhances peritoneal metastasis in gastric carcinomas.
  • OBJECTIVES: The role of Regenerating (Reg) IV on peritoneal metastasis was examined in gastric cancer using.
  • MATERIAL AND METHODS: Reg IV-transfected human gastric cancer cells (MKN28-R1, MKN28-R2, TMK1-R1), control transfectants (MKN28-R0, TMK1-R0), and REG4-knocked down MKN45 cells were examined in in vitro and in nude mice peritoneal metastasis models.
  • In mice models, increased number and size of peritoneal tumors and decreased apoptosis were found in Reg IV-transfectants, whereas those were abrogated by the knockdown cells.
  • Levels of Reg IV protein in peritoneal lavage fluids increased in Reg IV-transfectants inoculated mice, but decreased in Reg IV-knockdown cell inoculated mice.
  • In metastasized human gastric cancers, Reg IV positivity in peritoneum-metastasis cases was higher than those in negative cases.
  • Reg IV was detected in peritoneal lavage fluids from human gastric cancer patients, in whose lavages keratin mRNA was detected by reverse transcriptase-polymerase chain reaction.
  • Collectively, Reg IV might accelerate peritoneal metastasis in gastric cancer.
  • Reg IV in lavage fluids might be a good marker for peritoneal metastasis.
  • [MeSH-major] Lectins, C-Type / physiology. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology


84. Cabourne EJ, Roberts G, Goldin R, Ryder T, Mobberly M, Ziprin P: Investigation of tumor-peritoneal interactions in the pathogenesis of peritoneal metastases using a novel ex vivo peritoneal model. J Surg Res; 2010 Dec;164(2):e265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of tumor-peritoneal interactions in the pathogenesis of peritoneal metastases using a novel ex vivo peritoneal model.
  • BACKGROUND: Peritoneal metastasis occurs in up to 30% of patients with gastric cancer.
  • The aim of this experimental study is to develop and validate a novel ex vivo model of the human peritoneum to better identify factors involved in the development of peritoneal metastasis in order to improve its management and prognosis.
  • METHODS: Peritoneal discs harvested from hernia sacs obtained at inguinal hernia surgery were suspended in media using Teflon rings.
  • Modulation of tumor cell adhesion to peritoneum after exposure to heparin was assessed using a fluorometric adhesion assay.
  • Mesothelial cell loss at 48 h was demonstrated by LM and SEM, confirming peritoneal viability for at least 24 h after tissue harvesting.
  • Zymography confirmed increased MMP2 and -9 activities in tumor cells and peritoneal tissue during co-culture compared with controls, and heparin significantly reduced tumor cell adherence (P = 0.04), as observed in published in vivo models.
  • CONCLUSION: A validated complete model of peritoneum was developed that has shown potential to determine realistic mechanisms of peritoneal metastasis.
  • [MeSH-major] Hernia, Inguinal / surgery. Neoplasm Metastasis / pathology. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cell Adhesion. Cell Culture Techniques / methods. Cell Line, Tumor. Cell Survival. Coculture Techniques. Humans. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Microscopy, Electron, Scanning / methods. Peritoneum / pathology. Peritoneum / surgery. Peritoneum / ultrastructure. Prognosis. Stomach Neoplasms / enzymology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20951998.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


85. Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY: The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol; 2009 Jan;112(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
  • OBJECTIVE: The objective of this study was to determine the clinical significance of hepatic parenchymal metastasis on survival in patients with advanced epithelial ovarian cancer.
  • METHODS: We conducted a retrospective review of ovarian cancer patients with stages IIIc and IV hepatic parenchymal metastasis who were treated at the National Cancer Center in Korea between January 2001 and January 2008.
  • Hepatic metastases were divided into unresectable, hematogenous parenchymal metastasis and resectable, parenchymal metastasis from peritoneal seeding.
  • The stage IIIc group included 97 patients, and the group with stage IV disease and hepatic parenchymal metastasis included 16 patients.
  • Of the 16 patients with hepatic parenchymal metastasis, 2 patients had unresectable, hematogenous parenchymal metastasis with a poor prognosis compared to the patients with resectable, hepatic parenchymal metastasis from peritoneal seeding.
  • Fourteen patients with hepatic parenchymal metastases from peritoneal seeding underwent complete resection without complications as follows: wedge resection (n=7), segmentectomy (n=5), and hemi-hepatectomy (n=2).
  • Age, tumor grade, histology, serum CA-125 level, and the rate of optimal debulking were similar in patients with stage IIIc disease and patients with stage IV disease who had resectable, hepatic parenchymal metastasis from peritoneal seeding.
  • The 5-year progression free survival rate and the 5-year overall survival rate for patients with stage IIIc disease and patients with stage IV disease and hepatic parenchymal metastasis from peritoneal seeding were 25 and 23% (p=0.8063), and 55 and 51% (p=0.5671), respectively.
  • CONCLUSION: Our findings suggest that complete hepatic resection should be attempted for patients with hepatic parenchymal metastasis from peritoneal seeding.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies


86. Till H, Bergmann F, Metzger R, Haeberle B, von Schweinitz D, Prosst R: Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats. J Pediatr Surg; 2006 Aug;41(8):1357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats.
  • AIM: Fluorescence diagnosis is gaining clinical importance for the detection of malignancies in various medical disciplines.
  • The technique relies on the specific metabolic capacity of a lesion to produce a fluorescent compound.
  • METHODS: Human HB (3 x 10(6)) cells were laparoscopically injected (4 mm scope, 18-G needle) underneath the peritoneum of 7 nude rats (mean weight, 198 g).
  • Photosensitization was induced by peritoneal lavage with aminolevulinic acid (3%).
  • After 3 hours, the animals were investigated with white light laparoscopy (WL) and laparoscopic fluorescence diagnosis (LFD), applying the Storz PDD system.
  • CONCLUSION: Human HB can be detected with LFD in a rat model.
  • This finding opens a wide spectrum of experimental and clinical investigations to evaluate the impact of fluorescence diagnosis for pediatric oncology.
  • [MeSH-major] Fluorescence. Hepatoblastoma / diagnosis. Laparoscopy. Liver Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aminolevulinic Acid / metabolism. Animals. Cell Line, Tumor. Disease Models, Animal. Fluorescent Dyes / metabolism. Humans. Neoplasm Transplantation. Rats

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863837.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


87. Siquini W, Marmorale C, Guercioni G, Stortoni P, Bearzi I, Fianchini A, Landia E: [Solid pseudopapillary tumor of the pancreas. A report of 3 cases and a review of the literature]. Chir Ital; 2006 Mar-Apr;58(2):235-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SPTP is a rare neoplasm that has shown a progressive increase of incidence, passing from 0.17%-2.7% of all exocrine tumours of the pancreas in the 1980's, to 6% in recent reports in 2003.
  • The diagnosis in most cases is based on compressive symptoms, pain or finding of a palpable mass, while in about 20% of the patients the finding is occasional during abdominal imaging performed for other pathologies.
  • Cytological examination in most cases permits the diagnosis of SPTP.
  • The malignancy of these neoplasms is attenuated and local with capsular invasion, lymp-node spread and, only rarely, liver and peritoneal metastases.
  • Only in one case was the preoperative diagnosis correct.
  • Only in one case (the DCP) the capsule and the surrounding parenchyma were infiltreted by neoplasm.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734174.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 47
  •  go-up   go-down


88. Oosterling SJ, van der Bij GJ, Bögels M, ten Raa S, Post JA, Meijer GA, Beelen RH, van Egmond M: Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg; 2008 Jan;247(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces.
  • Effective treatment is however relatively frequent complicated by peritoneal recurrences, which often originate from free-floating intraperitoneal tumor cells that implant on peritoneal surfaces.
  • We previously reported that surgical trauma promotes development of peritoneal metastases.
  • Also, human ex vivo models were used to study peritoneal tumor cell adhesion.
  • RESULTS: Peritoneal imprints of operated rats showed that direct damaging of the peritoneum resulted in enhanced adhesion of rat CC531 colon carcinoma cells to submesothelial extracellular matrix (ECM) proteins in vivo, which was confirmed by electron microscopy.
  • Additionally, the inflammatory reaction of the peritoneal cavity led to retraction of mesothelial cells, hereby also exposing ECM at peritoneal surfaces that had not been traumatized directly.
  • Furthermore, we demonstrated that beta1 integrin subunits represented the primary mediators involved in adherence to either isolated ECM components or excised traumatized rat and human peritoneum.
  • Importantly, incubation of CC531s cells with anti-beta1 integrin antibodies resulted in a significant decrease of tumor cell adhesion in vivo.
  • CONCLUSIONS: Surgical trauma results in exposure of ECM at directly and nondirectly damaged peritoneal surfaces, leading to increased beta1 integrin-dependent tumor cell adhesion.
  • Perioperative therapies, which aim to block beta1 integrin subunits, might therefore serve as new clinical tools for the prevention of peritoneal recurrences.
  • [MeSH-major] Antibodies / pharmacology. Antigens, CD29 / physiology. Colonic Neoplasms / surgery. Peritoneum / injuries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156927.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD29
  •  go-up   go-down


89. Contreras CM, Stanelle EJ, Mansour J, Hinshaw JL, Rikkers LF, Rettammel R, Mahvi DM, Cho CS, Weber SM: Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol; 2009 Dec 15;100(8):663-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma.
  • We sought to assess the incidence of occult intra-abdominal metastases identified at the time of staging laparoscopy for patients with either potentially resectable or locally advanced pancreatic adenocarcinoma (LAPC).
  • We also compared the rate of occult metastases in patients who underwent staging laparoscopy versus laparotomy.
  • RESULTS: Over a 4-year period, 25 patients with potentially resectable tumors and 33 patients with LAPC were staged with laparoscopy, with an equivalent prevalence of occult metastases found at laparoscopy (28% potentially resectable vs. 33% LAPC, P = 0.8).
  • Occult peritoneal metastases were more likely to be detected in patients with potentially resectable tumors that were explored via laparoscopy than via laparotomy (32% vs. 10%, P = 0.018).
  • CONCLUSIONS: Staging laparoscopy is more likely than open exploration to detect occult metastases.
  • [MeSH-minor] Aged. Female. Humans. Male. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19780095.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Low RN, Gurney J: Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging; 2007 Apr;25(4):848-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 24 slices were obtained during a 20-second breathhold.
  • For observer 1 the additional tumor included lymphadenopathy (47), peritoneal metastases (15), renal (1), liver (12), and osseous (2), while for observer 2 the corresponding values were lymphadenopathy (40), peritoneal (12), renal (1), liver (6), osseous (4), and gastrointestinal (1).
  • CONCLUSION: DWI is feasible in a single breathhold and provides additional clinically important information in oncology patients when added to routine abdominal MR sequences.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Contrast Media. Diffusion Magnetic Resonance Imaging / methods. Gadolinium
  • [MeSH-minor] Feasibility Studies. Female. Humans. Lymphoma / diagnosis. Male. Middle Aged. Retrospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17335018.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


91. Liu CG, Lu P, Lu Y, Wang SB, Chen JQ: [Rational approach to the management of IV stage gastric carcinoma with hepatic metastasis]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep;10(5):440-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rational approach to the management of IV stage gastric carcinoma with hepatic metastasis].
  • OBJECTIVE: To investigate the benefit of surgical resection on the prognosis of patients with advanced gastric carcinoma and liver metastasis.
  • METHODS: Data of 102 cases of advanced gastric carcinoma with liver metastases from 1993 to 2004 were studied retrospectively.
  • RESULTS: The half-, one- and two-year postoperative survival rates of gastric carcinoma patients with H(1) metastasis undergone palliative resections were 69%, 44% and 6% respectively, which were significantly better than those of patients not undergone resection(accepted by-pass procedure or exploratory laparotomy) (P=0.009).
  • The half-, one- and two-year postoperative survival rates of gastric carcinoma patients with H(2) metastasis undergone palliative resections were 56%,13% and 6% respectively, which were not significantly different compared with those of patients not undergone resection(P=0.068).
  • The half-, one- and two-year postoperative survival rates of gastric carcinoma patients with H(3) metastasis undergone palliative resections were 25%, 13% and 0, which were not significantly different compared with those of cases not undergone resection (P=0.157).
  • Regardless of peritoneal metastases, there were no significant differences between the survival rate of resection group and that of non-resection group.
  • CONCLUSIONS: Gastric carcinoma patients with H(1) metastasis would benefit from palliative resection regardless of peritoneal metastasis.
  • Gastric carcinoma patients with H(2) or H(3) metastasis are not benefit from surgical resection.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851784.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


92. Low RN, Sebrechts CP, Barone RM, Muller W: Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol; 2009 Aug;193(2):461-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study.
  • OBJECTIVE: The purpose of our study was to evaluate the utility of single-shot spin-echo echo-planar diffusion-weighted imaging (DWI) using a b value of 400-500 s/mm(2) for depicting peritoneal tumors.
  • At three separate sessions, two observers independently reviewed images for peritoneal tumors at 16 anatomic sites.
  • Sensitivity, specificity, and accuracy were calculated for DWI, conventional MRI, and combined DWI and conventional MRI for peritoneal tumor depiction.
  • RESULTS: Two-hundred fifty-five sites of peritoneal tumor were proven by surgical and histopathologic findings.
  • The combination of DWI and conventional MRI was most sensitive and accurate for peritoneal tumors, depicting 230 and 214 tumor sites for the two observers (sensitivity, 0.90, 0.84; and accuracy, 0.91, 0.88) compared with DWI alone, which depicted 182 and 182 tumor sites with sensitivity (0.71, 0.71; and accuracy, 0.81, 0.81), and conventional MRI alone, which depicted 185 and 132 tumor sites (sensitivity, 0.73, 0.52; and accuracy, 0.81, 0.72).
  • Peritoneal tumor showed restricted diffusion on DWI and ascites was of low signal intensity, increasing tumor conspicuity.
  • CONCLUSION: Adding DWI to routine MRI improves the sensitivity and specificity for depicting peritoneal metastases.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Ovarian Neoplasms / pathology. Pseudomyxoma Peritonei / diagnosis. Retrospective Studies. Sensitivity and Specificity. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620444.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Kimura Y, Taniguchi H, Yano H, Miyazaki S, Nakamura H, Danno K, Kanoh T, Ohnishi T, Tono T, Nakano Y, Kagawa K, Monden T, Imaoka S: [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2499-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy].
  • We report a case of liver metastasis from gastric cancer that was effectively controlled with stereotactic radiation therapy (SRT).
  • A 77-year-old man underwent total gastrectomy, splenectomy, cholecystectomy and D2 dissection in February 2007 for type 3 gastric cancer in the upper third area that was diagnosed well to moderately differentiated adenocarcinoma and Stage II (T3 (SE) N0 H0 P0 CY0 M0).
  • He suffered from the liver and peritoneal metastases with ascites in December 2007, so S-1 was administered.
  • Ascites was disappeared, but liver metastasis was enlarged.
  • Therefore, SRT (total of 52.8 Gy per 4 fractions) was performed for the liver metastasis.
  • It is thought that SRT is one of effective treatments for liver metastasis from gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Radiosurgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224619.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Larghi A, Lecca PG, Ardito F, Rossi ED, Fadda G, Nuzzo G, Costamagna G: Evaluation of hilar biliary strictures by using a newly developed forward-viewing therapeutic echoendoscope: preliminary results of an ongoing experience. Gastrointest Endosc; 2009 Feb;69(2):356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Obtaining a definitive tissue diagnosis in patients with hilar biliary strictures (HBS) is often difficult.
  • RESULTS: Visualization and puncture of the primary lesion with a definitive tissue diagnosis was obtained in all of the 4 cases performed.
  • Metastatic hilar cholangiocarcinoma and recurrent neuroendocrine tumor were diagnosed in 2 patients and followed by placement of a self-expandable metal stent, when possible.
  • In the other 2 patients, a diagnosis of resectable hilar cholangiocarcinoma and poorly differentiated adenocarcinoma of unclear origin without evidence of vascular involvement was made, and plastic stents were placed before surgery; the first patient was found to have peritoneal metastases, and resection was aborted, and in the second patient, a gallbladder tumor was diagnosed in the surgical specimen.
  • [MeSH-major] Cholestasis, Intrahepatic / diagnosis. Endosonography / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Biopsy, Fine-Needle. Cholangiocarcinoma / diagnosis. Female. Humans. Male. Middle Aged. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185697.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Li ZR, Wang Z, Zhu BH, He YL, Peng JS, Cai SR, Ma JP, Zhan WH: Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. Surg Today; 2007;37(8):646-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis.
  • PURPOSE: In gastric carcinoma, high expression of PRL-3, a protein tyrosine phosphatase, is associated with lymph node metastasis.
  • We studied the relationship between PRL-3 expression and peritoneal metastasis in gastric carcinoma.
  • METHODS: Immunohistochemical analysis using the anti-PRL-3 antibody was done in 639 patients with gastric carcinoma including 89 with peritoneal metastases.
  • RESULTS: PRL-3 was expressed in 70.4% of the primary gastric carcinomas overall; in 80.9% of the cancers with peritoneal metastasis and in 68.7% of those without peritoneal metastasis (P = 0.020).
  • PRL-3 expression was higher in peritoneal metastasis than in the corresponding primary gastric cancers (P = 0.028).
  • PRL-3 expression was correlated with tumor stage (coefficient = 0.343, P = 0.01) and cancer progression, including lymphatic invasion (coefficient = 0.325, P = 0.02), extent of lymph node metastasis (coefficient = 0.322, P = 0.01), and peritoneal metastasis (coefficient = 0.316, P = 0.03).
  • CONCLUSIONS: Peritoneal metastasis appears to be correlated with PRL-3 expression, tumor stage, lymphatic invasion, and extent of lymph node metastasis.
  • PRL-3 expression was negatively correlated with prognosis in patients with gastric cancer.
  • [MeSH-major] Lymph Nodes / physiopathology. Neoplasm Invasiveness / physiopathology. Neoplasm Proteins / metabolism. Peritoneal Neoplasms / secondary. Protein Tyrosine Phosphatases / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):619-24 [12478012.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):961-76 [12461518.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1153-61 [12402156.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):370-5 [15739249.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • (PMID = 17643206.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


96. Eichel L, Kim IY, Uribe C, Khonsari S, Basillote J, Steward E, Coad J, Bischof J, Rudie E, Kluge S, McDougall EM, Clayman RV: Third Prize: Comparison of radical nephrectomy, laparoscopic microwave thermotherapy, cryotherapy, and radiofrequency ablation for destruction of experimental VX-2 renal tumors in rabbits. J Endourol; 2005 Nov;19(9):1082-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanism of potential tumor metastasis was also explored.
  • MATERIALS AND METHODS: The VX-2 tumor line is an aggressive rabbit epidermoid tumor with a high metastatic potential.
  • In view of these results, a second experiment was performed in which 45 New Zealand White rabbits were implanted laparoscopically with VX-2 xenografts underneath the kidney capsule and divided into five groups of 9 each.
  • RESULTS: At 5 days after tumor implantation, laparoscopic inspection revealed no visible peritoneal metastases.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283844.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Mutinelli F, Vascellari M, Bozzato E: Unilateral seminoma with multiple visceral metastases in a duck (Anas platyrhynchos). Avian Pathol; 2006 Aug;35(4):327-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral seminoma with multiple visceral metastases in a duck (Anas platyrhynchos).
  • A case of unilateral seminoma with visceral metastases in a Mallard duck (Anas platyrhynchos) is reported.
  • In addition, multiple rough whitish nodules were evident on the pancreas and the visceral peritoneum lining the intestine.
  • Multiple lung metastases were detected on histology.
  • This is the first known report of seminoma with hepatic, pancreatic, pulmonary and peritoneal metastases in a Mallard duck.
  • [MeSH-major] Liver Neoplasms / veterinary. Lung Neoplasms / veterinary. Peritoneal Neoplasms / veterinary. Poultry Diseases / pathology. Seminoma / veterinary. Testicular Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854647.001).
  • [ISSN] 0307-9457
  • [Journal-full-title] Avian pathology : journal of the W.V.P.A
  • [ISO-abbreviation] Avian Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Enestvedt CK, Mayo SC, Diggs BS, Mori M, Austin DA, Shipley DK, Sheppard BC, Billingsley KG: Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era? J Gastrointest Surg; 2008 Jul;12(7):1177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: For patients with potentially resectable pancreatic cancer, diagnostic laparoscopy may identify liver and peritoneal metastases that are difficult to detect with other staging modalities.
  • The aim of this study was to utilize a population-based pancreatic cancer database to assess the cost effectiveness of preoperative laparoscopy.
  • MATERIAL AND METHODS: Data from a state cancer registry were linked with primary medical record data for years 1996-2003.
  • De-identified patient records were reviewed to determine the role and findings of laparoscopic exploration.
  • CONCLUSION: Cost analysis indicates that the case-specific or routine use of laparoscopy in pancreatic cancer does not add significantly to the overall expense of treatment and supports the use of laparoscopy in patients with known or suspected pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparoscopy / economics. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / economics. Neoplasm Staging / methods. Oregon. Pancreatectomy. Preoperative Care / economics. Preoperative Care / methods. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Nov 1;89(9):1917-24 [11064348.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):325-37 [11260096.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):768-76 [11400971.001]
  • [Cites] Oncology. 2006;70(1):71-80 [16465066.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):36-42 [17390184.001]
  • [Cites] Gastrointest Endosc. 1999 Apr;49(4 Pt 1):498-503 [10202066.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1708-13 [10925972.001]
  • [Cites] Surg Endosc. 2001 Oct;15(10 ):1129-34 [11727085.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1286-92 [16332484.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):675-82 [9632157.001]
  • [Cites] Surg Endosc. 2005 May;19(5):638-42 [15776215.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):249-53 [11314942.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):1-7 [11753036.001]
  • [Cites] Am J Surg. 1996 May;171(5):533-7 [8651403.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):476-82 [8672153.001]
  • [Cites] J Am Coll Surg. 1998 Jan;186(1):35-40 [9449598.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):409-14; discussion 414-5 [10768705.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):649-55; discussion 655-7 [10359358.001]
  • [Cites] Arch Pediatr Adolesc Med. 1999 Sep;153(9):965-8 [10482214.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):189-99 [16236756.001]
  • (PMID = 18470572.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res; 2009 Feb 15;69(4):1469-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.
  • Ovarian cancers metastasize by attaching to and invading through the mesothelium, a single layer of mesothelial cells lining the peritoneal cavity.
  • The presence of invasive peritoneal metastases is associated with a poor prognosis for ovarian cancer (5-year survival <25%).
  • Membranous VCAM-1 expression was observed on the mesothelium of 13 of 14 women with ovarian cancer compared with 6 of 15 who were cancer-free.
  • Furthermore, using a mouse model of ovarian cancer metastasis, treatment with VCAM-1 function-blocking antibodies decreased tumor burden and increased survival.
  • Together, these observations implicate VCAM-1-alpha(4)beta(1) integrin interactions in the regulation of ovarian cancer cell mesothelial invasion and metastatic progression and offer the possibility of novel therapeutic targets.
  • [MeSH-major] Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Vascular Cell Adhesion Molecule-1 / genetics
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Cell Movement. Cell Survival. Epithelium / pathology. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Metastasis. RNA Interference. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2009 Mar 15;69(6):2694
  • (PMID = 19208843.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


100. Nervi M, Gambaccini D, Ambrosini CE, Berti P, Miccoli P: Overall prognosis in younger patients with colorectal carcinoma. Minerva Chir; 2006 Oct;61(5):381-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Prognosis of colorectal cancer in younger patients is a controversial issue.
  • While survival after curative resection seems not worse than in older patients, few data are available about the overall survival of younger patient with colorectal cancer irrespective of receiving a curative treatment or not.
  • In this study we have reviewed our experience with patients under 45 years of age affected by colorectal cancer.
  • METHODS: A total of 358 patients with colorectal cancer were operated on between 2001 and 2005.
  • CONCLUSIONS: Prognosis for colorectal cancer in the overall group of patients less than 45 years is worse than in older patients.
  • Younger patients more frequently present with distant metastases or peritoneal carcinosis which preclude the possibility of a curative treatment.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159745.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement